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Available online xxxxSkin cancer is a high burden disease with a high impact on global health. Conventional therapies have several
drawbacks; thus, the development of effective therapies is required. In this context, nanotechnology approaches
are an attractive strategy for cancer therapy because they enable the efficient delivery of drugs and other bioac-
tive molecules to target tissues with low toxic effects. In this review, nanotechnological tools for skin cancer will
be summarized and discussed. First, pathology and conventional therapies will be presented, followed by the
challenges of skin cancer therapy. Then, themain features of developing efficient nanosystemswill be discussed,
and next, themost commonly used nanoparticles (NPs) described in the literature for skin cancer therapywill be
presented. Subsequently, the use of NPs to deliver chemotherapeutics, immune and vaccine molecules and
nucleic acids will be reviewed and discussed as will the combination of physical methods and NPs. Finally, mul-
tifunctional delivery systems to codeliver anticancer therapeutic agents containing or not surface
functionalization will be summarized.








Skin cancer is classified as melanoma skin cancer (MSC) or
nonmelanoma skin cancer (NMSC). NMSC is the most commonly diag-
nosed type of cancer worldwide [1], and MSC is associated with the
highest percentage of deaths [2,3].
Therefore, skin cancer is a disease of global health importance that
causes substantial psychosocial impacts and requires considerable in-
vestment in terms of treatments and technologies [4,5].
Among the technological advancements in cancer treatments, the
use of nanosystems has been an attractive strategy for delivering thera-
peutic agents. These systems can be developed to overcome biological
barriers and to target drug delivery to the tumor sites, thus enabling
the use of lower doses, increasing treatment efficacy and decreasing
the number and/or severity of the side effects [6–8]. The benefits of
using nanosystems for cancer treatments are obvious, although most
of the nanotechnology approaches are at the research or development
stage, some of them have reached the clinical stage and are already on
the market. For instance, Doxil®, a PEGylated liposome containing
doxorubicin, is on the market and is indicated mainly for breast andal Sciences of Ribeirao Preto,
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tients [6]. Another nanotechnology product that was approved by the
FDA in 2005 is Abraxane®, an albumin-bound paclitaxel nanoparticle
that is indicated for the treatment of various cancers, especially meta-
static breast cancer and non-small-cell lung carcinoma [7,8].
For skin cancer, to the best of our knowledge, there are no commer-
cially available nanosystems for bioactive molecule topical delivery. Al-
though most nanoparticles (NPs) applications are still in the preclinical
stages, some studies have advanced and shown promise, leading these
nanotechnology products to be evaluated in clinical trials. For instance,
a clinical trial was recently started for cutaneous metastasis. The study
(ClinicalTrials.gov Identifier: NCT 03101358) aims to evaluate a topical
NP containing paclitaxel for the treatment of cutaneous metastases
from nonmelanoma cancer. The study is evaluating the safety, tolerabil-
ity and preliminary efficacy of three concentrations of this NP [9]. An-
other phase I study is evaluating the safety, maximum tolerated dose,
pharmacokinetics, and clinical activity of a liposomal miR-34a mimic
(MRX34) in patients with advanced solid tumors. The introduction of
miR-34a mimics into in vitro cancer cell lines derived from solid tumors
such as skin cancer resulted in an important reduction in cell prolifera-
tion, migration and invasion [10].
Nanotechnology approaches represent an opportunity to improve
the treatments for different types of cancer, and this review aims to
compile and discuss important works using these nanotechnological
tools for skin cancer. First, pathology and conventional therapies will
be addressed. Then, the challenges to skin cancer treatment will betrini, et al., Nanotechnology approaches in the current therapy of skin
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temic delivery of NPs loaded with different kinds of drugs as well as
multidrug resistance (MDR). Then, the designs and ideal characteristics
of NPs for effective delivery of drugs for skin cancer therapywill be pro-
posed according to the route of administration, followed by the presen-
tation of the main nanocarriers used for drug delivery in skin cancer.
Subsequently, treatment strategies for skin cancer using NPs to deliver
chemotherapeutics, immune and vaccine molecules and nucleic acids
will be reviewed and discussed. Finally, combinations of physical
methods and NPs and the use of multifunctional delivery systems will
be summarized and examined.
2. Pathology of skin cancer and conventional therapies
2.1. Melanoma skin cancer (MSC)
MSC originates in melanocytes, which are the cells that produce
melanin. In this pathological process, several mutations can occur,
mainly located in the epidermis, at the basal layer [11,12].
Several risk factors are related to MSC development, but the main
risk factor is excessive ultraviolet (UV) light exposure. This exposure
may trigger mutations in melanocytes that lead to invasive and meta-
static features [13].
The main mutations observed in melanomas involve the BRAF/
NRAS/MEK/MAPK pathways, mainly because these signaling pathways
are already operating aberrantly, even without mutations, in this type
of skin cancer. Thus, they are recurrent targets for therapies aimed at
treating melanoma. Unfortunately, current therapies confer MDR,
which requires increasingly innovative treatments that act simulta-
neously and aggressively on the melanoma pathways [13,14]. The
MDR effect is discussed in Section 3.2.
The treatments chosen for MSC depend on the stage of the disease
and include conventional therapies such as surgical excision and radio-
therapy (RT) and innovative treatments such as targeted therapy; im-
munotherapy; and combinations of systemic, topical and transdermal
therapies. When there is no metastatic ability, MSC shave a cure rate
of 90%; however, in contrast, the survival of patients with metastasis
drops to only approximately 10% [1,11,12].
Surgery is indicated for lesions with well-defined borders, but there
are risks of lymph node involvement, metastases and relapse [15].
The primary treatment for patients with good prognoses and well-
defined lesions is RT. RT has satisfactory tumor reduction rates and is
safe and well tolerated [16]. Additionally, RT can be used to treat more
advanced stages when associated with other therapies, such as immu-
notherapy [17].
The molecular mechanisms of MSC have not been entirely eluci-
dated; therefore, treating the disease is difficult. To overcome this chal-
lenge, innovative therapies are required that are mainly based on
delivery systems using nanotechnology.
2.2. Nonmelanoma skin cancer (NMSC)
NMSC, as opposed to MSC, develops along well-known molecular
pathways; hence, therapeutic platforms are more efficient in NMSC
than for MSC. Moreover, because it is less aggressive and has lower in-
vasive potential, NMSC is associated with better prognoses and survival
rates than MSC [18].
Squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) orig-
inate in keratinocytes and are known as keratinocyte carcinomas. BCC is
more prevalent than SCC, accounting for approximately 70% of the
cases, compared with 25% for SCC. Neither type contributes to deaths
from skin cancer; nevertheless, they are considered a significant public
health problem due to their high incidence, the fact that they are more
prevalent than all other types of cancers worldwide, and the burden
that they represent [5,19].Please cite this article as: L.N. Borgheti-Cardoso, J.S.R. Viegas, A.V.P. Silves
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crease an individual's predisposition to develop this type of neoplasia.
The main factors, in addition to genetics, are age; exposure to UV rays
and/or ionizing radiation, immunosuppression, genodermatoses, HPV
infection, medications such as TNF-α inhibitors, tobacco use, severe
skin and/or bone infections, and inflammatory conditions [18–23].
Surgery is an option for the treatment of NMSC; however, depending
on the extent of the lesions and their locations, nonsurgical treatments
are highly recommended, especially for lesions with well-defined mar-
gins and those presenting in relatively confined areas. Themain nonsur-
gical treatments are curettage, electrodesiccation, topical drug
administration, cryosurgery and radiation and photodynamic therapies
[20,24]. The treatment of choicemay vary depending on the lesion area,
location, and molecular pathway.
Several kinds of NPs have been widely used for the treatment of
NMSC due to their ability to deliver drugs through several molecular
pathways simultaneously and to be administered through different
routes to prioritize less invasive pathways.
3. Challenges to skin cancer treatment
3.1. Biological barriers
In current skin cancer therapies, NPs loaded with anticancer agents
are generally administered through topical/transdermal, intratumoral
(local), or systemic (intravenous) routes or through a combination of
these. Topical or transdermal applications are noninvasive and self-
administered approaches considered for elderly patients, those not
considered candidates for surgical treatment, and young patients with
extensive lesions in areas of cosmetic importance [25]. These adminis-
tration routes have been used for most premalignant lesions, such as
those of AK; superficial skin cancer, such as noninvasive SCC; and BCC
and melanoma in the initial stages [26].
The outermost epidermal layers of the skin, constituting the stratum
corneum (SC), are themain cutaneous barrier and influence the uptake
of anticancer agents into target cells, consequently affecting the re-
sponse to topical or transdermal treatments. Typically, in human skin,
the SC is composed of approximately 15–30 corneocyte cell layers,
which provide a thickness of approximately 10–20 μm. The layers are
formed as the product of long epidermal maturation, differentiation
and keratinization processes. These processes are induced in the
deepest epidermal layers that rest on the basal lamina above the dermis
to constitute the basal layer [27]. Additionally, several types of lipids
surround corneocytes, such as ceramides, triglycerides, cholesterols,
and free fatty acids, to form a complex network of lipids and
corneocytes that can absorb water and control the penetration of mac-
romolecules and micromolecules through the skin.
The viable epidermis is another epidermal layer that is localized
below the SC and reaches the dermal-epidermal junction formed by
the thin basal layer [28]. In contrast to the dermis, the viable epidermis
is vascularized, and although it is composed mainly of keratinocytes at
different stages of maturation, the viable epidermis is also populated
by melanocytes, Langerhans cells and Merkel cells and ranges in thick-
ness from 50 to 100 μm [29].
The dermis is vascularized and responsible for providing nutritional
support to the viable epidermis. Lymphatic vessels, sebaceous glands,
collagen, elastin, sensory nerves, and hair follicles are localized in the
dermis and are arranged within an area that is approximately 0.1 to
0.4 cm thick [30].
Skin cancerwith cutaneousmorphology presents an over expression
of keratin, high levels of lipids, and the presence of erythematous
plaques, keratotic papules or nodules compared to healthy tissue
[31,32]. Several skin cancer subtypes present with an increased amount
of keratin, which leads to diffusion-resistant tissue and results in a sig-
nificant barrier to the passive transport and retention of NPs in the tar-
get cells [31,33]. Generally, AK lesions produce excessive keratin,trini, et al., Nanotechnology approaches in the current therapy of skin
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penetrate. Therefore, NPs used against AK need to be properly designed
to pass through the SC and reach the deeper epidermis layer, where the
Langerhans cells are located, to exert immune responses [34].
Considering themost advanced stage of skin cancer, in which tumor
cells extend throughout the epidermis and dermis, several associated
treatments have shown better success rates than topical application
alone, for example, the combination of topical application and physical
methods and the combination of topical and systemic applications. As
discussed later (Section 6.4), the enhanced penetration of NPs through
the skin by physical methods occurs due to disorganization of the skin
barrier such that channels are formed between the corneocytes and/or
the keratinocytes. The combination of NPs and physical methods is
convenient for the patient because topical drug delivery reduces
the first-pass effects and side effects that can occur with systemic
administration [35].
However, when topical and systemic applications are combined, NP
biodistribution is governed not only by the skin barrier but also by other
biological barriers [33]. For instance, the first biological barriers encoun-
tered after systemic NP administration are related to the hepatic and
renal clearance that removes NPs from the circulation. The structure of
the blood vessels under ordinary conditions prevents NP penetration
and decreases their retention at the tumor site [36]. In contrast, in can-
cer, the blood vessels in tumors present fenestrations and endothelial
imperfections that create heterogeneous canals with openings of 200
to 2,000 nm that facilitate the penetration of NPs across blood vessels
and promote NP delivery to target cells [36]. The combination of these
mechanisms, such as poor lymphatic drainage and imperfect blood ves-
sels in tumors, creates an abnormal microenvironment that increases
drug delivery into and through the skin [37,38].
Another biological barrier consists of the dense tumor interstitial
space composed of collagen, proteins, elastic fibers, and glycosamino-
glycans. Because the interstitial fluid pressure is elevated in this condi-
tion, the transport of drugs to the interior of tumors is affected.
Additionally, the extracellular matrix, which in the tumor environment
is excessively rigid andhas an elevated collagen content, acts as a barrier
to the transport of theNPs to the cancer cells [33,39].Moreover, features
of the NPs influence their interaction with tumor cells, their connection
to the components of the cells and the physiological characteristics of
the cells. Themain interactions between theNPs and tumor cells are ad-
sorption, cellular uptake, and endosomal transport, followed by
endosomal escape, metabolism, and degradation [36]. Donahue et al.
(2019) discussed the cellular internalization pathways of NPs and how
the cellular interactions, trafficking and kinetics may be affected by
the physicochemical properties of the NPs [40]. Overall, the cell plasma
membrane is a cellular uptake barrier to NPs due to its negative surface
charge, resulting in selective permeability to biomolecules andNPs. This
cellular barrier must be overcome via different routes (e.g., direct cellu-
lar entry of the NPs or entry via endocytosis pathways) to see a biolog-
ical response. For passive entrance into the cell, these delivery systems
are translocated across the cell plasma membrane through the lipid bi-
layer, and then, the NPs are delivered into the cytoplasm, thus overcom-
ing the endosomal entrapment and energy-dependent transport
mechanism. During uptake in endocytosis-based pathways, the NPs
are restricted within intracellular vesicles until they are released into
the cellular cytoplasm.
For transport via endocytosis, different mechanisms may be in-
volved, such as micropinocytosis, phagocytosis, caveolin-independent
endocytosis, caveolin-dependent endocytosis, clathrin-independent en-
docytosis and clathrin-dependent endocytosis [40–42]. NPs after uptake
are captured by endosomes, and NPs can be designed to escape and be
readily available to act at the specific target site [40,43].
For intratumoral application, NPs can be injected at high concentra-
tions, thus avoiding possible side effects compared to other administra-
tion routes. This administration route is minimally invasive, enables the
use of low doses, decreases immunostimulation reactions and is lessPlease cite this article as: L.N. Borgheti-Cardoso, J.S.R. Viegas, A.V.P. Silves
cancer, Adv. Drug Deliv. Rev., https://doi.org/10.1016/j.addr.2020.02.005painful than subcutaneous injection [44]. Moreover, the tumor itself is
a potential site of vaccination through direct intratumoral immuniza-
tion, enabling an increase in vaccinemagnitude and enhancing the con-
trol of metastasis [45,46]. Injectable gel generated in situ has also gained
considerable attention from researchers in the past few years for
intratumoral administration [47,48].The gel formed in situ from a pre-
cursor fluid can absorb water from the environment and swells as a re-
sult, and after self-assembling in the gel, the anticancer agent is released
in a sustained manner [48].
3.2. Multidrug resistance (MDR)
Nanotechnology is an exciting and promising alternative for over-
coming multidrug resistance (MDR), since through this tool, it is possi-
ble to provide treatment in a specific, orderly way, with smaller doses of
therapeutic agents and fewer toxic effects. The use of nanocarriers en-
ables the effective, targeted delivery of several therapeutic agents
made from combinations of molecules aimed at acting synergistically
and effectively against cancer types that are resistant and no longer re-
sponsive to conventional therapies [49–54].
MDR occurs when tumor cells acquire resistance to various drugs
used in therapy. This MDR situation is illustrated by the significantly re-
duced therapeutic potency of a drug that culminates in the progression
of the disease. MDR is considered an obstacle to the effective therapy of
several types of cancer, including skin cancer, especially melanoma
[55–57].
TheMDR effectmay arise due to intrinsic and/or acquired factors. In-
trinsic factors are related to drug degradation, alteration of prodrugs, al-
teration of drug targets and receptors, and reduction in drug-receptor
interactions. Additionally, membrane changes, metabolic process alter-
ations, cell cycle changes, repairs to DNA damage, and changes in efflux
pumpsmay contribute toMDR. The acquired factors are, in turn, usually
associated with epigenetics. Patients who present with intrinsic factors
do not respond to conventional treatments; patients who acquire resis-
tance present with decreased effectiveness of treatments over time
[55,56].
The molecular mechanisms that lead to this resistance can be de-
fined as noncellular or cellular mechanisms. Noncellular mechanisms
are those inherent to the tumor and its characteristics, such as pH,
whichmakes the tumor environment hostile to the otherwise appropri-
ate action of the drugs. Cellular mechanisms are caused by biochemical
changes in the tumor cells. The main known mechanisms involved in
skin cancer are changes in drug uptake, efflux pumps, and enzymatic ac-
tivation; alterations in DNA repair; avoidance of apoptosis pathways;
and P53 alterations (Fig. 2).
NPs have been used to overcome theMDR effects [54]. For example,
changes in efflux pumps can lead to the uptake of active agents in tumor
cells. NPs are widely employed to overcome theseMDR effects on efflux
pumps. For example, a hybridmicelle containing a prodrug of doxorubi-
cin was developed to overcome this MDR mechanism. The MDR effect
on efflux was overcome by this NP, and the drug was efficiently deliv-
ered in tumor cells, where as previously, there were problems in uptake
[58]. Drugs, such as temozolomide, have been encapsulated in NPs to
overcome the difficulty in thembeinguptake in tumor cells. Dendrimers
containing temozolomide had improved uptake inmelanoma cells [59].
Liu et al. (2012) used silver NPs decorated with penetrating peptide
(TAT) to overcome the MDR effects that transpired during the NP up-
take process. Through this functionalization, the uptake was improved,
and consequently, the antitumor activity was more effective [60]. Guo
et al. (2018), in turn, overcameMDR effects usingmesoporous titanium
dioxide NPs that combined the following functions: target, drug deliv-
ery, and PDT. The active compounds were CD44, N-cadherin, and doxo-
rubicin [61].
Aiming for the apoptotic cascade, Chen et al. (2009) chose to target
the BCL-2 protein to overcome MDR effects. The authors developed
mesoporous silica nanoparticles to codeliver doxorubicin and Bcl-2trini, et al., Nanotechnology approaches in the current therapy of skin
Fig. 1. Main steps of NP development, (a) Choice of formulation components; (b) Choice of preparation technique; (c) Control of the preparation and NP characteristics; (d) exhaust
mechanisms; (e) Choice of targets and (f) multifunctional therapies as example: target and specific therapy such as the use of siRNA.
4 L.N. Borgheti-Cardoso et al. / Advanced Drug Delivery Reviews xxx (2020) xxxsiRNA, and the results indicated that BCL-2 was an important target for
melanoma treatment, and inhibition of BCL-2 was crucial for overcom-
ing the effects of MDR on the apoptotic cascade [62].
4. Design and characteristics of the NPs
4.1. Design
The design and characterization of NPs carrying anticancer drugs
have reached the first stages of application for effective skin cancerFig. 2. Themain knownmechanisms for skin cancer that promotemultidrug resistance (MDR),
interaction between nucleotide binding domains and drug [51,55,57,351,352]; (c) Inhibition of
Mcl-1) and down expression of pro-apoptotic molecules (Bax) [50,351]; (d) Reduction of ce
glutathione conjugation (GSH) catalyzed by glutathione S-transferase enzyme (GST) [56,57]. C
Please cite this article as: L.N. Borgheti-Cardoso, J.S.R. Viegas, A.V.P. Silves
cancer, Adv. Drug Deliv. Rev., https://doi.org/10.1016/j.addr.2020.02.005treatment with few adverse effects. The development of NPs needs
to follow specific steps, and the final design is reached according to
the nature of the NP chosen, target location and type of therapy de-
sired, as illustrated in Fig. 1. Each administration route (topical,
transdermal, intratumoral or systemic) has its own biological obsta-
cles and characteristics; therefore, the therapeutic target tissue
and the ideal administration route are important factors to be
considered. Thus, this coordinated approach has great potential to
optimize NP design and create a new frontier for skin cancer
therapy [39,40].(a) Alterations of receptor sites for drugs [55,57]; (b) Changes in efflux pumps through the
the caspase cascade through the overexpression of anti-apoptotic molecules (Bcl-2, Bcl-xl,
llular uptake of drugs by modification of membrane lipids and inactivation of drugs by
IT = cytosol.
trini, et al., Nanotechnology approaches in the current therapy of skin
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areas: effective penetration through the SC barrier and accumulation
in the epidermal layer at therapeutic concentrations. It has already
been shown that small molecules can penetrate the skin by one of
three possible pathways: the intercellular route (through the lipid ma-
trix that surrounds the corneocytes), the transcellular route (across
the corneocytes and into the lipid matrix) and the transappendageal
route, represented by sweat ducts, hair follicles and sebaceous glands
[63]. However, for hydrophilic molecules greater than 500 Daltons,
such as peptides, and nucleic acids, topical and transdermal delivery
are very difficult [64]. Alternatively, NPs can overcome the SC and target
tumor cells,whether combinedwith physicalmethods or not, by SC bar-
rier disruption and the increase in the drug diffusion due to altered
membranes.
NP features, such as particle size and particle size distribution, shape,
surface charge, surface function, and chemical nature, can be designed
to fit the therapeutic approaches [65]. Thus, well-designed systems
should be able to (i) solve drug solubility issues, mainly those related
to highly hydrophobic drugs, (ii) encapsulate the anticancer agent in
its internal structure to improve drug stability by chemical or physical
means, (iii) provide delivery of encapsulated drug by controlled or
sustained release rates and (iv) reduce skin irritation by avoiding direct
drug-skin contact [34]. Additionally, when systemically administered,
NPs should have the ability to (i) overcome the lymphatic drainage sys-
tem, (ii) remain for a long time in the bloodstream and (iii) reach the
therapeutic site at effective doses. Target molecules, such as antibodies,
can be used to increase the accumulation of NPs at desired sites [33,64].
However, the process for manufacturing NPs presents several chal-
lenges that havemade it difficult to scale up production and to translate
the NPs created at the bench into clinical practice [66]. In turn,
predicting the morphology, particle size, polydispersion index, surface
changes (in chemistry, adhesion and charge), encapsulation or com-
plexation efficiency, drug release kinetics, hemodynamic activity and
steric stabilization level of the NPs during the early pharmaceutical de-
velopment process has been the key to achieving a better correlation
between use in vitro and in clinical trials [67].
4.2. Particle size features
In general, the particle size predicts much about the ability of an NP
to penetrate the skin as well as its systemic biodistribution, and there-
fore, the size has a significant impact on drug pharmacokinetics, partic-
ularly drug biodistribution and cellular uptake, and safety [68].NPs from
6 to 30 nmwere able to penetrate the skin via intracellular/intercellular
routes and aqueous pores. Particles ≤30 nm penetrated the skin in a
manner that depended on their surface polarity, hydrophilicity, shape,
andmorphology. Other particles ≤70nmwere deposited in both epider-
mal and dermal layers, with preferential accumulation in cutaneous ap-
pendages, while particles ≥600 nm were retained on the SC to form an
occlusive film on the skin [69,70]. To NPs fully penetrate the skin and
reach the bloodstream under stable conditions, despite the cutaneous
appendages to be present in only small portions of the skin, they seem
to be the main contributors to NPs directly penetrating the skin and
reaching the bloodstream under stable conditions [71], and flexible li-
posomes can also be carried across the intact skin through the
corneocyte bricks [72].
When applied systemically, particles ≤30 nm were rapidly cleared
from circulating blood by the renal excretion system; particles equal
to 100 nmhad an increased blood circulation time compared to smaller
particles; large particles, between 200 and 300 nm, were retained
mainly in the spleen and liver; and those ≤400 nm underwent rapid he-
patic clearance [68,73]. It is worth noting that particles smaller than
200 nm benefited from the EPR effect, thus favoring targeting of the
tumor [68].
Nonetheless, after direct intratumoral injection, particles of approx-
imately 65 nm penetrated the tumor environment until reaching thePlease cite this article as: L.N. Borgheti-Cardoso, J.S.R. Viegas, A.V.P. Silves
cancer, Adv. Drug Deliv. Rev., https://doi.org/10.1016/j.addr.2020.02.005cancer cells, while particles between 85 and 120 nmwere easily extrav-
asated to the venous outflow immediately after intratumoral injection.
Others particle sizes of approximately 178 nm were retained in the
tumor interstitium [74,75]. Rigorous control of particle size is an impor-
tant taskwhen transitioning from lab-scale preparation to a larger-scale
manufacturing process. NP size distribution needs to be well controlled
in the manufacturing process because it influences the penetration and
retention behavior of these systems. However, although simultaneous
cutaneous penetration through different routes may favor heterogene-
ity, the overall process is more unstable [76].
4.3. Shape features
The modulation of the NP shape and surface can predict particle de-
livery [77]. Particle shape plays an essential role in skin penetration as
well as subcellular targeting [33,78–80]. NPs that are rod-shaped, spher-
ical and triangular were investigated for their ability to penetrate differ-
ent layers of skin. To determine these parameters, follicular and
intracellular penetration pathways were considered [81].
Triangular NPs were observed to penetrate the skin more slowly
than rod-like and spherical NPs. Furthermore, the rod-like NPswere ob-
served to penetrate and subsequently accumulate at higher levels in the
dermal layer, which enhanced their systemic effects [81]. The subcellu-
lar trafficking of anticancer agents was most favorable using rod-like
NPs, according to a study in which they localized in the nucleus in met-
astatic cancer cells after 2 h of NP treatment in vitro [82]. On the other
hand, inhibition of the cellular uptake and subcellular trafficking of dis-
coidal NPswas also observed because they localized in the phospholipid
membrane bilayers and thus had a lower tendency to penetrate human
cells.
Carbon nanotubes were reportedly compatible with and transport-
able in biological fluids and entered human cancer cells by endocytosis
or needle-like penetration, enabling direct NP cytoplasmic delivery [83].
With this in mind, discoidal and cylindrical shaped NPs are considered
potential templates for designing cell membrane-specific and safe
theranostic imaging agents for applications in skin cancer treatment
[69]. Overall, nonspherical particles demonstrated higher performance
than spherical counterparts.
4.4. Surface features
The role of theNP surface is crucial in predictingNP cytotoxic effects,
activity, and efficacy when they are intravenously administered, as
demonstrated by NPs coated with blood components in the
opsonization process to make them targets for clearance by macro-
phages [68]. In turn, a well-designed particle surface can improve the
actions on specific cellular targets, enhance cellular uptake and localiza-
tion in the target cell of the NPs and prevent serum effects [84,85]. Par-
ticle surfaces charged with either positive potential or negative
potential improved nanosystem stability by preventing agglomeration
and flocculation processes through the enhanced electrostatic repulsion
between the particles [86]. Moreover, positively charged particles in-
crease particle binding to the target cells via electrostatic interactions
to a greater degree than negatively charged or neutral molecules be-
cause of the negative charge of the cellular plasmamembrane. Likewise,
negatively charged phospholipids are abundantly distributed in the
tumor cell membranes [76]. In addition, positive particle surfaces can
be engineered based on cationic compounds (lipid or polymer) that
favor the complexation of nucleic acids such that they can penetrate
the cell membrane and subsequently release the nucleic acid into the
cytoplasm or the nucleus to improve the results of the gene therapy
used in cancer treatment [87,88].
Regarding systemic administration, onewell-known surfacemodifi-
cation is the PEGylation coating, which confers a prolonged half-life and
superior overall efficacy to NPs compared with that presented by
“nonstealth” NPs. This approach decreases NP affinity for thetrini, et al., Nanotechnology approaches in the current therapy of skin
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removal from circulation as well as increases their uptake by cancer
cells [89]. Other surface-modified NP strategies include the use of anti-
bodies, proteins, aptamers, and folate [90–92],which traffic NPs directly
to targeted receptor-positive tumor cells to subsequently penetrate the
cell by receptor-mediated endocytosis. However, the effectiveness of NP
therapeutic activity is achieved only when the therapeutic agent is lo-
calized to the proper target located in the cytoplasm, mitochondria, or
nucleus and avoids lysosomal degradation [33].
On the other hand, for topical administration, optimization of the
cell uptake and trafficking was further enhanced after the NP surface
was decorated with targeted cell-penetrating peptides (CPPs) [93–95].
Among several CPPs, transcriptional activator (TAT) and sensitive ma-
trix metalloproteinases (MMPs), which are over expressed in skin can-
cer cell membranes and upregulated in the interstitial tumor space,
respectively, have been extensively investigated [93,94]. These CPPs
can translocate across the cell membrane and deliver both charged
and noncharged NPs, which have enhanced accumulation in tumors
[69,94].
Finally, in the field of cancer vaccines, inorganic NPs have gained at-
tention due to additionally providing imaging contrast for theranostics
or susceptibility to magnetic navigation that is used to increase tissue-
specific accumulation [96]. Bocanegra et al. (2018) used zinc-doped
iron oxide magnetic NPs to deliver a combination of TRL agonists and
peptide antigens. The vaccines showed superior efficacy against aggres-
sive B16F10 melanoma cells. Additionally, the researchers could track
the vaccine transport from the site of injection to the LNs and tumor
by nuclear imaging andmagnetic resonance (MR) [97]. Other examples
of NP delivery systems include the use of lipid-coated zinc phosphate
hybrid NPs [98], liposome-coated gold NPs [99] andmultiwalled carbon
nanotubes [100].
Some functionalization of NP surfaces aiming to target tumor cells
and/or increase the blood circulation time of NPs are discussed later in
Section 6.5.
4.5. Intracellular trafficking features
The site of action for several important drugs that are used for the
treatment of different diseases is the intracellular organelle. For exam-
ple, the anticancer drug doxorubicin acts in the nucleus. Therefore, it
is essential to design NPs that enable the drug to reach its targeted site
of action, surpassing the challenges of intracellular delivery, such as ly-
sosomal degradation and the size restriction of organelle entry [101].
Rationally designed, multiple stimuli-responsive NP approaches
were recently explored as promising tools for improving the intracellu-
lar trafficking of anticancer agents through rapid cytoplasmic delivery
[102]. The most explored stimuli-responsive NPs were designed to tar-
get changes in pH, temperature, redox condition, enzyme activity,
magnetic field, ultrasonic waves and various types of irradiation
[103,104]. For these purposes, biocompatible polyglycerol-based
thermoresponsive nanogels showed intracellular localization in lyso-
somal compartments after 24 and 48 h of treatment, indicating that
the lysosomes are the final intracellular fate of the nanogels in cutane-
ous cells [105]. Polymer-coated CNPs, being nontoxic for stromal cells,
showed cytotoxic, proapoptotic, and anti-invasive abilities against cuta-
neous melanoma cells, with cytosolic distribution [106]. In another ap-
proach, CPP-targeted NPs with redox-sensitive coatings accumulated to
the highest level in tumor tissue but not in healthy organs [107],
resulting in optimized intracellular trafficking, greater antitumor effi-
cacy and improved safety compared to those that already have the ap-
proval of the Food and Drug Administration (FDA) [90].
The intracellular trafficking of molecules with different characteris-
tics is distinct. There are few studies in the skin cancer field attempting
to complete the understanding of intracellular drug delivery. An appre-
ciation and description of these pathways is essential to the proposal of
effective NPs.Please cite this article as: L.N. Borgheti-Cardoso, J.S.R. Viegas, A.V.P. Silves
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It is well known that nanotechnology is an important tool for thera-
peutic agent delivery in cancer therapies. The rational development of
nanocarriers for anticancer drugs has led in advanced systems that
can act to target cancerous tissues and cells [108]. Given the magnitude
of events and barriers involved in skin cancer, several types of NPs have
been proposed and can be initially classified according to the main for-
mulation component [109]: for instance, lipid-based nanoparticles such
as liposomes, transferosomes, niosomes, ethosomes, solid lipid NPs, and
liquid crystalline nanodispersions; polymeric-based carriers such as
polymer NPs, polymeric micelles, and dendrimers [110]; and inorganic
nanostructures (Fig. 3). In this section, the main nanocarriers used for
drug delivery in skin cancer will be presented.
The combination of nanostructured therapeutic agents in NPs with
dosage forms is yet a new and little-explored alternative for delivering
NPs [111]. These NPs can be incorporated into dosage forms such as
creams [112,113] ointments and hydrogels [114,115], patches
[113,116] for topical penetration [115,117,118].
5.1. Lipid-based NPs
Lipid NPs are the most conventional nanocarriers and are mainly
represented by lipid vesicles, known as liposomes, which are able to
carry lipophilic and hydrophilic drugs [119,120]. These colloidal carriers
are composed of lipids and phospholipids that have the advantage of
being identical to physiological compounds [110]. Most liposomes are
phospholipid-based vesicles that bear a long hydrophobic chain and a
hydrophilic head and have the ability to self-assemble [120]. These
NPs improve the penetration of hydrophilic molecules, which are en-
capsulated in the aqueous core, or hydrophobic molecules in the mem-
brane bilayers [121]. In addition, amphiphilic molecules can also be
loaded into a liposome core using specific preparation methods [122].
The composition, flexibility, and deformability of such nanocarriers
can be adjusted according to the need [120]. Therefore, since large lipo-
somes are excluded from the deep skin layers, small and mostly mono-
disperse liposomes with a diameter of approximately 30–40 nm can be
obtained by a microfluidic procedure to enhance the ability of these
lipid NPs to penetrate the skin [123]. Moreover, the mixture of lipo-
somes with biocompatible copolymers led to the formation of vesicles
with an increased ability to permeate into the deep skin layers in studies
in vitro [124].
Transfersomes, deformable vesicles used for drug delivery to the
skin, penetrate through the SC pores by squeezing themselves along
an intracellular sealing lipid [110,125]. Hydrating synthetic nonionic
surfactants in the presence or absence of cholesterol or other lipids
leads to the formation of niosomes [108,110].
Noninvasivenanocarriersmainly formulatedwithphospholipids, etha-
nol, andwater are called ethosomes and are found in variable proportions
in ethanol [113]. Improving the penetration of drugs into deep skin layers
using these NPs was first described by Touitou et al. (2000) [126].
Small-sized carriers in the lipidmatrix release drugs based on the in-
fluence of the matrix and nanoparticle components [127]. Among these
particles are solid lipid NPs, which range from 50 to 1,000 nm and are
composed of physiological lipids that can organize themselves and
form a dispersion in water or aqueous surfactant solutions [110]. Nano-
structured lipid carriers are second-generation lipid NPs tailored with a
solid matrix including liquid lipids at a ratio ranging from 70:30 up to
99.9:0.1 [120,128].
Among the lipid-based delivery systems, the liquid crystalline sys-
tems also have the capacity to incorporate hydrophilic, lipophilic and
amphiphilic molecules as well as to modulate the release of these mol-
ecules based on the phase inwhich NPs are produced. These liquid crys-
talline NPs are formed from lyotropic liquid crystals that can be
classified in mesophases, such as lamellar, hexagonal and cubic phases
(11). Each mesophase will generate nanosystems with specifictrini, et al., Nanotechnology approaches in the current therapy of skin
Fig. 3. Main types of nanoparticles used in skin cancer therapy: (a) lipid-based NPs, (b) polymer-based NPs and (c) inorganics.
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ferent behaviors in the incorporation of molecules; iii) physical stabili-
ties; and iv) degree of tissue penetration [48,129,130].
5.2. Polymer-based NPs
Polymeric NPs have several attractive properties as drug delivery
systems, such as ease of manipulation, the potential forPlease cite this article as: L.N. Borgheti-Cardoso, J.S.R. Viegas, A.V.P. Silves
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trol over behavior in vivo, biodegradability and biocompatibility
[131,132]. Polymeric NPs are most commonly administered by sys-
temic, intravenous injection, although the use of such nanocarriers
with many therapeutic agents that can be delivered across biological
membranes is currently in development [132]. Protein NPs provide di-
verse interactions with drugs and three-dimensional networks to offer
several reversible drug molecule assemblies [133].trini, et al., Nanotechnology approaches in the current therapy of skin
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pylene oxide)-poly(ethylene oxide) (PEO-PPO-PEO) [134]. The PPO
unit is a hydrophobic segment that contributes 30% of the copolymer
content, and the PEO unit is the hydrophilic segment of the polymer.
Pluronic F127® is a copolymer that has gained attention due to its
vast therapeutic applications [134]. The hydrophobic core PPO, which
creates the environment for lipophilic drug incorporation, is formed
from Pluronic F127®. Therefore, the PEO segment prevents adsorption
and aggregation of an incorporated protein [134].
Matsumura et al. (2004) was the first to develop polymeric
nanocarriers, polymeric micelles of PEG-poly(amino acid), which suc-
cessfully and efficiently accumulated in solid tumors in mice and ad-
vanced to clinical trials [132,135,136]. The incorporation of drugs into
polymeric micelles can occur by physical, chemical, or electrostatic in-
teractions [137,138]. An example of a polymeric micelle formulation is
Genexol-PM (PEG-poly(D,L-lactide)-paclitaxel), a polymeric micelle-
formulated paclitaxel [122,138]. In contrast, polymer-drug conjugates
are macromolecular agglomerates formed by one or more therapeutic
agents, such as small drug molecules, proteins, and peptides, attached
by covalent bonds to the polymeric carrier structure [132].
Since proteins are natural polymers with heterogeneous polymer
sizes and a range of molecular weights, heterogeneous NP size distribu-
tions can exhibit batch-to-batch variations [139]. Suitable rawmaterials
include animal proteins such as gelatin, collagen, albumin, silk proteins
and elastin since they have absorbability and their degradation products
induce low toxicity compared to synthetic polymers [133]. Moreover,
the presence of amino and carboxylic functional groups makes them
easy to bindwith, which is useful for targeting ligands and surfacemod-
ifications [122].
Elastin-like polypeptide NPs are also an interesting drug delivery
system for several applications [133,140]. These particles are excellent
candidates due to their combined amphiphilic behavior, biodegradabil-
ity, and biocompatibility in a single system. Recently, elastin-like poly-
peptide NPs were synthesized because of their ability to penetrate
deep into tumor tissue after temperature-induced coassembly with
CPPs such as octa-arginine [140] and to reversibly self-assemble into
micellar structures for photodynamic therapy [141]. Additionally, NPs
obtained from plant proteins such as zein and gliadin present a new ap-
proach for NP production since they have some advantages [142], al-
though NPs created with them may need chemical modification or
physical treatment due to the high hydrophobicity of these proteins.
Other polymer-based NPs, such as polymersomes, which are com-
posed of liposomal membranes from amphiphilic polymers, have also
gained increased attention due to the structural variability of such
membranes [143]. A hybrid polymeric NP/hydrogel system was devel-
oped and evaluated for the permeation of benzocaine in vitro and for
tracking the NPs in the artificial membrane [144] as a strategy for
skin drug delivery. Wakabayashi et at. (2018) developed a solid-in-oil
(S/O) nanodispersion for transcutaneously delivering hydrophilicmole-
cules, which was an attractive system [145]. Nanoscale hydrogels in the
submicrometer range are often called nanogels and are prepared by
chemically or physically cross-linking polymers [146]. This polymer
networkmay range in size up to a fewhundred nanometerswhen swol-
len in water [146] and has been recently been exploited for cancer im-
aging and drug delivery vehicles [122].
The conjugation of therapeutic agents to polymeric carriers also of-
fers several advantages. The rational design and recently revealed ad-
vantages of this strategy is discussed in [132].
5.3. Inorganic NPs
Inorganic nanocarriers have been investigated for imaging and treat-
ment due to their large surface area, improved drug loading capacity
with decreased toxic side effects [122,147], high biocompatibility and
size-dependent magnetic properties [148]. Gold nanorods have been
explored for biomedical applications [149,150] and photothermicPlease cite this article as: L.N. Borgheti-Cardoso, J.S.R. Viegas, A.V.P. Silves
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[151]. However, gold nanostructure-based plasmonic hybrids have
been developed to have superior performance in PTT [152,153].Manga-
nese dioxide (MnO2) NPs have been used due to their high reactivity
with endogenoushydrogen peroxide (H2O2)within the tumormicroen-
vironment to generate O2, thus overcoming tumor photodynamic resis-
tance by generating O2in situ [154,155].
The proliferation rate of cancer cells is high and is also regulated by
the cell cycle and DNA replication, and ruthenium-based anticancer
drug candidates are used in one strategy to address DNA damage as
one of the many metallotherapeutics approved by the US Food and
Drug Administration [156,157]. Therefore, the metallopolymer prodrug
formed by covalent conjugation of the ruthenium complex to the poly-
mer can be converted into an active drug at a controllable rate [156]. A
combination of photodynamic therapy (PDT) and PTT is currently pro-
viding promising applications in cancer therapy and is overcoming the
inherent limitation of PDT, such that it has achieved attention for
malignant tumor treatment, even surpassing conventional treatment
technologies such as chemotherapy and radiotherapy, due to its
minimally invasive nature, precise application and localized scope of
treatment [151].
Carbon nanotubes are synthetic nanomaterials that are well known
for the ideal near-infrared PDT potential that gives them the capability
to increase the temperature within tumors [158,159]. Water-soluble
carbon nanotubes are being investigated for gene and drug delivery
due to their nontoxicity, ease in crossing biological barriers and ability
to transport molecules to the cytoplasm [160]. Moreover, the associa-
tion of the dual plasmonic agents in such a hybrid construct demon-
strates the enhanced physicochemical properties of both agents and
shows outstanding functionality by combining the effects of two differ-
ent nanostructures [161,162].
In the case of inorganic NPs, their drug delivery potential and
imaging capabilities have grown quickly in recent years. These
“nanotheranostic” NPs have been broadly used for treatment and diag-
nosis in breast and liver cancer; however, for skin cancer, few studies
have been published [131,163]. Although there are limited studies on
skin cancer, the published works showed interesting theranostic NPs
for melanoma treatment and detection, which justifies more research
in this area. For instance, gold NPs functionalized with anti-nucleolin
aptamer (AS1411) and iron oxide NPs functionalized with IR80 have
proven to be efficient magnetic resonance imaging probes that induce
selective cytotoxicity in A375 melanoma cells after irradiation with
an NIR laser [164,165]. In another study, cobalt ferrite oxide
(Co0.5Fe2.5O4) nanotubes loaded in nanoemulsions showed intense
time-dependent accumulation in a murine melanoma xenograft
model, providing MRI imaging potential. Recently, a new approach to
tumor monitoring and therapy using photoacoustic and ultrasonic
tools was investigated by Li et al. (2018). They developed a multifunc-
tional polymeric NP loaded with gold nanorods (Au-NRs) and liquid
perfluorocarbon that was conjugated with a monoclonal antibody
(MAGE-1 antibody). They observed that the theranostic NPs specifically
targeted melanoma tumor cells with high persistence at the site in vivo
[166]. In another study, elastin-like polypeptide (ELP)-conjugated gold
NPs exhibited photothermal properties. Additionally, a single
intratumoral injection of ELP-gold NPs provided simultaneous
photothermal/photoacoustic/X-ray computed tomographic imaging
and PTT of the melanoma [167].
5.4. Other NPs
Therapeutic agents conjugation to polymeric carriers also offers sev-
eral advantages. Polymer–drug conjugate therapeutics are constructs
that comprise one or more therapeutic agent, and among them the
first market approved polymer-protein conjugate, Adagen [132].
Ekladious et al (2019) discuss the advances in different classes of
polymer–drug conjugates, such as polymer–protein and polymer–trini, et al., Nanotechnology approaches in the current therapy of skin
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cles [132]. Moreover, electrostatic interactions of cationic polymers
with negatively charged nucleic acids such as plasmid DNA or small in-
terfering RNA (siRNA) led to the so-called polyplexes [168–170]. Since
cationic lipids also can provide negative charges, these structures are
used for complexation of genetic material. The structure of these so-
called lipoplexes depend on cationic lipid composition, helper lipids
and the DNA or RNA [171,172]. Lipopolyplexes are constructs that com-
bine cationic liposomes, cationic polymers and the RNAor DNA via non-
covalent interactions [173–175].
6. Treatment of skin cancer by NP drug delivery
In this section, different nanocarriers (presented in Section 5) used
for the delivery of chemotherapeutics, immunotherapeutic and vaccine
molecules and nucleic acids will be discussed.
6.1. Chemotherapies
Chemotherapy with drugs such as dacarbazine, temozolomide,
nitrosoureas, vinca alkaloids, taxanes and cisplatin has been used for
cases of advanced MSC [176–178]. 5-FU is an actively and widely used
drug for the treatment of skin cancers, such as actinic keratosis and
basal cell carcinomas [179]. However, 5-FU is highly hydrophilic,
which limits it to ability to reach tumor tissues though the SC [180].
Dacarbazine has a short half-life and is a poorly soluble active drug;
it is used as a single-agent FDA-approved anticancer drug and is the
drug of choice for use in chemotherapy against MSC [112,181]. This
drug has been encapsulated in lipid NPs for topical delivery in MSC
treatment [112]. More complex NPs were developed by Liu et al.
(2017), who rationally designed a nanocarrier based on hollow meso-
porous silica NPs enveloped with folic acid-grafted liposomes [182].
Carboplatin, a second-generation platinum compound also recom-
mended by the FDA for the treatment of melanoma, was loaded into
poly(ε-caprolactone) NPs with a chitosan-β-glycerophosphate gel for
intratumoral administration [47]. Additionally, an antitumor effect
in vitro and in a xenograft tumor model in vivo were evaluated by Su
et al. (2017), who produced paclitaxel-loaded copolymer NPs [183].
The antitumor doxorubicin was encapsulated into polymeric NPs, and
this, via self-assembly induced with polyphosphazenes, generated a
pH-responsive amphiphilic polymer [184].
Solid lipid NPs were used as a delivery system for temozolomide,
which was preliminarily investigated for MSC treatment [185]. In the
studies of Jian et al. (2017), a temozolomide-loaded polyamide-amine
dendrimer in a PAMAM delivery system was explored for use in
targeting human melanoma cells in vitro [59].
6.2. Immunotherapy and therapeutic vaccines
The immune system is of paramount importance in cancer develop-
ment. In a successful antitumor response, tumor-associated antigens
(TAAs) are presented by antigen-presenting cells (APCs) to T cells,
such as dendritic cells (DCs), either at tumor sites or in draining
lymph nodes (LNs). The activation of T cells occurs when their receptors
engage peptides presented by the APCs in major histocompatibility
complex (MHC) molecules. Later, these effector cells travel across the
tumor vasculature, penetrating the tumor tissue. Inside the tumor,
these tumor-infiltrating lymphocytes (TILs) recognize TAAs on tumor
cells to kill them, releasing more antigens and thereby enhancing anti-
tumor activity [186,187]. However, cancer cells are able to avoid or
block immune surveillance by down regulating MHC I molecules, over-
expressing the ligands that inhibit T cell detection, or releasing immu-
nosuppressive molecules that limit the function and proliferation of
effector T cells and permit the recruitment of immunosuppressive
cells, such as regulatory T cells (Tregs), to the tumor site and allow
them to proliferate [188,189]. In skin cancer, the immunosuppressionPlease cite this article as: L.N. Borgheti-Cardoso, J.S.R. Viegas, A.V.P. Silves
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[190,191], Merkel cell carcinoma (MCC) [192], Kaposi sarcoma (KS)
andMSC [193], demonstrating the importance of normal cutaneous im-
munity in eliminating nascent skin tumors. For a deeper understanding
of the basis of oncoimmunology, we refer readers to a review [187].
In recent years, research in the field of immunotherapy has resulted
in a growing number of clinical trials and the approval of several immu-
notherapeutic drugs [194,195]. Moreover, the Nobel Prize in Physiology
and Medicine of 2018 was awarded to James Allison [196] and Tasuku
Honjo [197] for their discovery of the CTLA-4 (cytotoxic Tlymphocyte-
associated antigen 4) and programmed cell death 1 (PD-1) immune
checkpoints [198].
Immune checkpoints are inhibitors in signaling pathways that regu-
late the immune system to maintain central and peripheral tolerance
and control systemic inflammatory responses in the body [199]. Im-
mune checkpoint inhibitors are monoclonal antibodies directed against
immune checkpoint proteins expressed on the surface of neoplastic
cells. The CTLA-4 receptor is expressed on T cells and downregulates
its activation at the early stages of the immune response by competing
with CD28 to bind CD80 and CD86 on APCs [200,201]. Moreover, it
upregulates Treg activity, which also diminishes the immune response.
Ipilimumab, a human IgG1 monoclonal antibody against CTLA-4, im-
proved the survival of patients with advanced malignant melanoma
and was approved by the FDA in 2011 [202,203].
Clinical benefits have also been observed for the PD-1 receptor and/
or its ligands, such as PD-L1. PD-1 is expressed on many activated im-
mune cells, and PD-L1 is found in many tissues to limit autoimmunity.
However, tumor cells that have been induced to overexpress PD-L1 by
proinflammatory cytokines inactivate infiltrating T cells after PD-L1
binds to PD-1 [204,205]. Thus far, five FDA-approved drugs are available
for the treatment of several types of cancers through systemic adminis-
tration, including pembrolizumab and nivolumab (anti-PD-1) for mela-
noma and avelumab (anti-PD-L1) for Merkel cell carcinoma [206], with
response rates as high as 50% [207]. Clinical trialswith SCCpatients have
shown promising results [208].
Despite the promising results, systemically administered checkpoint
inhibitors present several limitations, such as resistance and low dura-
ble response rates [209,210], severe side effects in numerous organs
[211], and no response in many treated patients [206,212]. Moreover,
different tumor microenvironments have different mechanisms of im-
munosuppression [213]. Recent studies have explored other immune
checkpoints and are reviewed elsewhere [199].
The first immune therapy strategy for the treatment of MSCwas the
use of cytokines, which resulted in increased overall patient survival.
This strategy is aimed at directly promoting the growth and activity of
immune cells. Granulocyte-macrophage colony-stimulating factor
(GM-CSF), interleukins and interferons are the three most essential
agents. In 1998, the FDA approved the use of interleukin-2
(aldesleukin), a protein that triggers the proliferation of T, B, and NK
cells [214].Interferon-α (Intron A)was approved in 1996 as an adjuvant
treatment for use against malignant MSC after surgical resection.
Interferon-α promotes antitumor immunity by inducing thematuration
of immune cells and increasing TAAexpression on tumor cells [206]. De-
spite their long-term use in the clinic, the short half-life of cytokines in
circulation results in the need for high-dose administration, which
causes numerous unwanted side effects, such as potentially fatal capil-
lary leakage and cytokine release syndrome [206,214]. To address
these drawbacks, versions of these cytokines that circulate for long pe-
riods have been investigated. PEGylated versions of IFN
(peginterferon-alfa-2b) [215,216] and IL-2 were investigated but
showed no clinical benefits [195,196]. Moreover, the continual adminis-
tration of either version of cytokine has been associated with the devel-
opment of neutralizing antibodies for both the native protein and its
therapeutic counterpart [186].
Another strategy is adoptive T cell therapy (ACT), which involves ex-
pansion and cellular engineering of patient-derived lymphocytes ex vivotrini, et al., Nanotechnology approaches in the current therapy of skin
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ACT currently in development involve TILs, chimeric antigen receptor
(CAR) T cells and T cell receptor (TCR) T cells. Among these, TILs have
shown promising results in the control of metastatic melanoma
[217–219]. The development of TILs consists of the extraction of sup-
pressed lymphocytes that have recognized and infiltrated the tumor
and expansion of them ex vivowith the use of cytokines that reactivate
these cells. However, one major hurdle of this approach is the high cost
and the need for skilled labor. TCR and CAR T cells are developed by ge-
netically engineering T cells by introducing TCR or CAR proteins to con-
fer specificity for tumors [220]. Despite the sustained responses in the
control of metastatic melanoma, these TCR-modified cells have induced
off-tumor toxicity [221]. CAR T cell technology shows an important ad-
vantage over TCR-based methods and their limitations, as there is no
need for MHC identification or costimulation by interleukins [220].
However, the therapeutic success of CAR T cell technology is restricted
to hematological cancers [220,222]. However, its effect on solid tumors
needs to be validated (reviewed elsewhere [200]).
Cancer vaccines are designed to be potential mechanisms that
generate a long-lasting response to cancer development by stimulating
immune memory of TAAs. These TAAs may be overexpressed tumor-
self-antigens or neoantigens generated by a tumor-specific mutation,
but they are not present in healthy tissues [186,223]. Cancer vaccination
with nucleic acids can be DNA-based or RNA-based. For this strategy to
be effective, themRNA or DNAmust be taken up by the APCs and trans-
lated to induce antigen expression. Although nucleic acid vaccination
has shown interesting results inmelanoma animalmodels, clinical trials
showed no significant clinical outcomes, often because of barriers to nu-
clear delivery and immunogenicity [224]. Vaccination with TAA pep-
tides is another exciting strategy for antitumor treatment. However,
the first trials investigated the infusion of free peptides with poor phar-
macokinetic profiles, which contributed to a response rate of less than
3% in clinical trials between 1995 and 2004 [186,225]. Recently, patients
were treated with two different approaches for personalized vaccines
formelanoma: RNA injection into lymph nodes [226] and subcutaneous
administration of synthesized peptides [227], with early phase trials
showing promising results. However, delivery of antigens to DCs in
the absence of concomitant inflammatory stimuli induced immunologic
tolerance rather than immunity. This finding indicates that the use of
antigens alone weakly induces adaptative immunity [228].
The increasing knowledge of cancer immunologyhas led to the com-
bination of vaccines with other agents of interest [228]. A phase III trial
with 185 patients with stage III or IV melanoma used a melanoma pep-
tide antigen vaccine (gp100) combined with IL-2 and showed a re-
sponse rate of 16%, compared to 6% with IL-2 treatment alone, and a
progression-free survival of approximately 2.2 months, compared to
1.6 months with IL-2 treatment alone. However, the patients experi-
enced toxic effects consistent with high-dose IL-2 administration
[229]. Nevertheless, the coadministration of free antigens and adjuvants
can lead to differential delivery to different DCs, thereby dampening the
immune stimulation.
Despite continuous advances in the field of immunotherapy, clinical
applications still encounter a variety of challenges. As discussed above,
these setbacks involve the development of resistance or a lack of re-
sponse to treatments, toxic effects related to therapies such as cytokines
or CART cell infusion, and the limited efficacy of cancer vaccines
[230–233]. Nanotechnology has been widely used to address similar
limitations in several medical fields.
In cancer immunotherapy, NPs can be directed to different cells and
tissues related to the immune response, such as APCs, lymphocytes and
lymphoid tissues [234], thereby overcoming the limitations of direct
cancer cell targeting [235]. Indeed, the use of nanoparticles associated
with T cells or natural killer cells has promoted a higher concentration
of drugs to be administered in tumor environments than the concentra-
tions when NPs are used alone [236–239]. Exploiting this strategy,
Schmid et al. (2017) used the FDA-approved polymers PLGA and PEGPlease cite this article as: L.N. Borgheti-Cardoso, J.S.R. Viegas, A.V.P. Silves
cancer, Adv. Drug Deliv. Rev., https://doi.org/10.1016/j.addr.2020.02.005to synthesize NPs with antibody fragments conjugated to their surfaces
to target PD-1-expressing T cells in the circulation and tumors. The de-
livery of a TGFβ signaling inhibitor to cells expressing PD-1 prolonged
the survival of tumor-bearingmice, whereas the free drugs had no effect
[240]. To safely deliver a nucleic acid, Li et al. (2016) developed 100 nm
polymersomes carrying siRNA against CTLA-4 and demonstrated their
ability to enter T cells both in vitro and in vivo. In mice bearing B16
melanoma, the researchers demonstrated NP uptake by TILs at tumor
sites after intravenous administration [241]. Researchers have also
demonstrated the combination of NPs with microneedles in MSC treat-
ments [242,243]. NPs were formed by covalent ligation of the
immunosuppressor indoleamine 2,3-dioxygenase (IDO) to hyaluronic
acid to form an amphiphilic structure that self-assembled to encapsu-
late anti-PD-1. After transcutaneous delivery in a B16F10 mouse mela-
noma model, tumor growth was significantly delayed, and 70% of the
treated group survived, compared to no survival in the untreated mice
[243].
NPs can also be used to facilitate the combination of immunother-
apies. Effective activation of immune cells often involves multiple sig-
naling pathways [187]. The administration of free immunomodulators
usually leads to only a few immune cell encounters and thus does not
provide the desired costimulatory effect. Park et al. (2012) designed bio-
degradable core-shell nanoparticles that combined the features of both
solid polymers and liposomal systems for a simultaneously sustained
release of a hydrophobic drug (β-cyclodextrin) and a hydrophilic cyto-
kine (IL-2). β-Cyclodextrin is an inhibitor of TGFβ, a primary negative
regulatory signal produced in tumors. After systemic administration of
these NPs, tumor growth was significantly delayed, and the survival of
tumor-bearing mice was enhanced. Additionally, the activity of natural
killer cells and intratumoral-activated CD8+ T cell infiltration were
increased in both subcutaneous and metastatic melanoma tumor
models [244].
The delivery of NPs can also be directed to the tumor microenviron-
ment. Kwong et al. (2013) anchored an engineered IL-2Fc fusion protein
and anti-CD137 (a costimulatory receptor upregulated on activated T
cells) to the surface of PEGylated liposomes. The intratumoral injection
of these particles into the B16F10 melanoma model enabled localized
stimulation of T cells without inducing systemic toxicity because the
size of the liposomes permitted dissemination through the tumor-
draining lymph nodes and tumor parenchyma but not into the systemic
circulation. This therapy using PEGylated liposomes curedmost primary
tumors, with the advantage of avoiding the lethal inflammatory toxic-
ities induced by equivalent intratumorally administered doses of solu-
ble agents [245].
Nanotechnology has also been used to address barriers to adoptive
immunotherapy. Major limitations include the need for a rapid increase
of antigen-specific T cells in culture and the decreased viability of the
transplanted cells that requires coadministration of adjuvants to maxi-
mize the performance of the cells.
Some approaches have considered the design of artificial APCs
(aAPCs), where proteins necessary for T cell activation are conjugated
to the particle surface [246]. Perica et al. (2014) designed iron-dextran
NPs functionalized with anti-CD28 antibodies and MHC-Ig dimers as
aAPCs that bind to TCRs. The use of a magnetic field enhanced the TCR
clustering at the T cell surface and reduced the threshold of activation
for T cells ex vivo, demonstrating that NP binding and cellular activation
are influenced by spatial organization at themembrane. Later, mice that
had been treated with T cells activated by nano-aAPCs had 8-to-10-fold
inhibited growth of B16melanoma lesions compared to untreatedmice
and to those in which the T cells were not subjected to the magnetic
field [247].
In a different approach to enhance ACT, T cell surfaces are function-
alized with NPs to influence their function in vivo. Stephan et al. (2010)
manufacturedmultilamellar lipid NPs encapsulating cytokines and con-
jugated them ex vivo to free thiol groups located on the surface of T cells.
This strategy provided pseudoautocrine stimulation to the donor cells,trini, et al., Nanotechnology approaches in the current therapy of skin
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prolonged survival of a B16F10 tumor mouse model with low doses of
adjuvant drugs administered subcutaneously; however, the treatment
was unsuccessful when systemic administration was used [217].
Nucleic acid vaccines have been gaining importance as promising al-
ternatives to conventional approaches. However, the DNA vaccines
tested in several clinical trials usually fail as a consequence of nuclear
delivery barriers and immunogenicity [248]. Although mRNA vaccines
are advantageous because they do not integrate into the genome and
can be delivered to the cytoplasm, they are quickly degraded by nucle-
ases and are not easily internalized by cells [249]. In this context, the use
of NPs can be beneficial [250,251]. A recent phase I trial was conducted
in patients treated with an mRNA that expressed four different TAAs in
complex with cationic liposomes. The liposomes protected the RNA
from extracellular degradation and mediated its efficient uptake by
the DC populations in various lymphoid compartments. Three treated
patients demonstrated strong immune responses against self-antigens
and showed either regression of metastatic lesions or disease stabiliza-
tion [250]. Another critical study demonstrated the possible usefulness
of subcutaneously delivered ionizable liposomes containing mRNAs
encoding the TAAs gp100 and TRP2. This strategy led to tumor shrink-
age and increased survival in treated melanoma-bearing mice [229].
Other RNA strategies include the use of short hairpin RNAs (shRNAs)
and small interfering RNAs (siRNA) [252–255].
An important advantage of using NPs for antigen delivery is their ca-
pability to carry several adjuvants or neoantigens, which is ideal for
treating different cancers [256]. To avoid inducing immunotolerance,
vaccine antigens are administered with an immune adjuvant, such
as a toll-like receptor ligand (e.g., cytosine-phosphate-guanine
oligodeoxynucleotides (CpGs)) or cytokine (e.g., IL-2 or GM-CSF). Kuai
et al. (2017) manufactured high-density lipoprotein nanodisks coupled
with antigen peptides identified via DNA sequencing of the tumor
exome and CpGs as an adjuvant. Strikingly, the NPs elicited up to 47-
fold higher frequencies of neoantigen-specific cytotoxic T lymphocytes
than free antigens plus CpGs. The combination of vaccination with im-
mune checkpoint inhibitors amplified the therapeutic efficacy and erad-
icated B16F10 tumors in N90% of the animal models, compared to
approximately 38% eradication in the control animals treated with
free antigens plus CpGs [257]. More than being useful for codelivering
adjuvants, certainmaterials can transform the NP itself into an adjuvant
[258]. PC7A, an ultra-pH-sensitive copolymer, has been shown to in-
duce a strong cytotoxic T lymphocyte response [259]. The derived
neoantigen nanovaccine showed a greater ability to stimulate immunity
than poly (I:C), a synthetic ligand of toll-like receptor 3, or CpGs in a B16
melanoma mouse model and resulted in 100% survival after 60 days
when administered in association with anti-PD-1 [259].
The studies discussed here have demonstrated the potential use of
NPs in promotingmore robust antitumor effects in cancer immunother-
apy in comparison to the administration of free drug. Although the field
of cancer immunotherapy has advanced rapidly, the use of nanotech-
nology is still in its initial stages and represents a wide and exciting
field for further consideration and investigation.
6.3. Gene therapy
Since the gene therapy approach was proposed in 1966, the use of
nucleic acids to restore or replace a defective or missing gene has been
extensively studied due to the benefit of these strategies [260–263]. Dis-
ease treatment by gene therapy can be implemented for three different
classes of genetic material and enables the knockin or knockdown of a
targeted gene depending on the genetic material transfected: plasmid
DNA (pDNA), RNA interference (RNAi) molecules or antisense oligonu-
cleotides (AONs) [260].
pDNA is widely employed to fix a nonfunctional gene or to re-
express an endogenous gene aiming to treat a genetic disorder; they
are used to permanently change gene expression [260]. For instance,Please cite this article as: L.N. Borgheti-Cardoso, J.S.R. Viegas, A.V.P. Silves
cancer, Adv. Drug Deliv. Rev., https://doi.org/10.1016/j.addr.2020.02.005for the treatment of MSC, Heller’s group developed a pDNA that
encoded interleukin-12 (IL-12) [264,265]. A pDNA is a double-
stranded DNA with a size of hundreds to thousands of bases organized
in a round shape. pDNA vectors consist of several components, such a
transgene, an enhancer, a promoter, transcription terminal signals,
splicing and polyadenylation sites, and antibiotic resistance genes. The
transgene is replicated independently of the chromosomal DNA of the
host and is divided into each cell that results from cell division. After
the vectors are internalized into the cytoplasm, they are imported into
the nucleus, and due to the promoter sequence, the specifically encoded
mRNA is transcribed. Following transcription, posttranscriptional mod-
ifications occur on the mRNA, and then, it is exported into the cyto-
plasm, where the mRNA is translated into protein [260].
Themechanismof action of RNAiwas established in 1998when Fire,
Mello, and colleagues showed that the administration of double-
stranded RNA (dsRNA) promoted the silencing of cytoplasmic messen-
ger RNA (mRNA) that contains a complementary sequence [266]. From
that point of discovery, RNAi has been widely studied, and dsRNA effec-
tor molecules, usually small interfering RNAs (siRNA), are used as tools
in the research of gene function [267,268] and for the identification of
potential disease-causing genes [269], offering a promising approach
for therapy [270–272]. The RNAi process can be split into two phases:
the initiation phase and the effector phase. In thefirst phase, the effector
molecules (siRNAs and microRNAs (miRNAs)) are created. The effector
phase comprises the real RNAi mechanism, in which the double-
stranded siRNAs and miRNAs are linked with cellular proteins to
generate an RNA-induced silencing complex (RISC). In the course of
RISC assembly, one strand (the passenger) is eliminated, while the
other strand (the guide) forms an active RISC. The single-stranded
(antisense) siRNA or miRNA of the activated RISC guides it to the com-
plementary target mRNA. The mRNA is cleaved by the protein
Argonaute 2 [270,273,274]. This native gene silencing pathway can be
used for the downregulation of chosen genes.
AONs are short single-stranded DNAmolecules (15–25 nucleotides)
that are complementary to the RNA strand and can specifically inhibit a
target mRNA. An AON hybridizes premRNA or mRNA, becoming the
substrate for the endogenous ribonuclease H (RNase H), which is an en-
donuclease that recognizes the mRNA oligo complex and cleaves the
RNA strand, leaving the AON intact, which can then bind to other target
RNA molecules [275]. For example, AONs targeting the c-myc gene re-
tarded the growth rate of melanoma cells [276].
Studies of the molecular mechanism have shown that cancer occurs
via the inactivation of cancer-suppressing genes or the activation of on-
cogenes, which results in a malignant tumor. Targeting cancer via gene
therapy can eliminate both problems by (a) inserting a gene that leads
to apoptosis or that increases tumor sensitivity to radiation/drug treat-
ments; (b) expressing a tumor suppressor gene to replace the loss/de-
regulation; (c) using an antisense (RNA/DNA) strategy to stop the
expression of an oncogene; or (d) increasing the immunogenicity of
the tumor to trigger immune cell recognition [263,277].
The administration of genetic cargo to the skin can be performed
using strategies ex vivo and in vivo. The strategy ex vivo comprises taking
human cells, fixing them via gene delivery and regrafting these fixed
cells into the patient. In the in vivo approach, the genetic material is
transferred directly to the skin. Although scientists are still struggling
to surpass the challenges of delivering genetic material directly to the
skin, the use of the ex vivo strategy is not feasible due to the costs,
pain and time associated with its clinical application [260].
For transdermal gene delivery, themajor hurdle is the SC because of
its structure, as discussed in Section 3.1. In addition to the SC barrier,
epidermal layers are also obstacles to topically applied genetic material.
After overcoming skin barriers, genetic material must overcome the
challenges inherent to its own physicochemical properties to reach
targeted cells and promote therapeutic activity [260]. Due to their
highmolecular weight, hydrophilic nature, and negative charge, nucleic
acids have low membrane permeability, which results in lowtrini, et al., Nanotechnology approaches in the current therapy of skin
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tion efficiency is entirely different between fibroblasts, keratinocytes,
dendritic cells, and macrophages. Another challenge to gene therapy is
neutralization and destruction of the genetic material provoked by im-
mune response activation [260].
To overcome these barriers, different approaches have been studied
that enhance gene delivery into and through the skin and deliver ge-
netic cargo to desired cells. Nonviral NPs (polymers, lipid-based carriers,
cell-penetrating peptides, dendrimers, and gold NPs) have been devel-
oped to improve macromolecule penetration through the SC barrier
and to induce the intracellular delivery of nucleic acids [279–281]. For
example, carbon nanotubes have been demonstrated to enhance trans-
dermal drug delivery. Based on this process, Siu et al. (2014) developed
a single-walled carbon nanotube for local delivery of siRNA. Treatment
of MSCs with a version of this system containing siRNAs specific to
BRAF (BRAFV-RAF murine sarcoma viral oncogene homolog B, an im-
portant gene in the MAPK pathway)decreased tumor growth over 25
days [279]. Spherical NPs conjugated to nucleic acid have gold cores
coated by a dense shell of siRNA, which are highly oriented,
immobilized and covalently bound. Within hours after application,
these NPs spontaneously penetrate almost 100% of the keratinocytes
in vitro, in mouse skin, and in the human epidermis [280]. A cell-
penetrating peptide and cationic poly(ethyleneimine)-conjugated gold
NP (AuPT) successfully enabled penetration of pDNA through the intact
SC. This NP was generated by compacting the pDNA into cationic
nanocomplexes and was highly efficient in the transdermal delivery of
pDNA without any required enhancement. The efficient transdermal
delivery and transfection of the pDNA encoding the miRNA-221 inhibi-
tor gene (Mi221) by AuPTs inmelanoma cells andmelanomaxenografts
in mice show that these nanocomplexes provide an excellent approach
for skin cancer gene therapy seeking to inhibit both the metastasis and
progression of advanced MSC [281].
NPs have also been developed to improve genetic material delivery
and transfection by local application [48,282,283]. For instance, siRNA
in complex with liposomes and administered intratumorally promoted
effective gene silencing, making it an interesting therapy for the treat-
ment of MSC [282]. Nanocomplexes formed with PEI and siRNA were
also used for delivering siRNA through intratumoral injection.
Intratumoral injection of PEI-siRNA complexes has also been used for
the inhibition of STAT3 in cancer. In this study, a linear low-
molecular-weight PEI was modified by N-acylation with lipidic side
chains. Stearoyl modified PEI (PEI-StA) resulted in an enhanced promo-
tion of STAT3 silencing in B16 cells and a reduction in VEGF production
in comparison with the unmodified PEI [283]. In situ solidified
organogels based on monoglycerides, propylene glycol, tris buffer and
polyethylenimine were developed for siRNA delivery. The addition of
PEI was crucial for the action of the siRNA. The siRNAs were released
complexed with PEI and in a controlled manner [284]. This system,
which was able to complex high amounts of siRNA, protected the
siRNA from degradation, promoted its internalization, and induced
gene knockdown in vitro in tumor cell lines. Moreover, in a murine xe-
nograft model of anepidermoid carcinoma, an in situ gel was formed
after intratumoral injection. Therefore, this in situ solidified organogel
is an interesting strategy to intratumorally deliver siRNA [48].
Although there are promising studies of nonviral carriers for gene
therapy to treat skin cancers, there are few examples that show their
use alone. Physical methods (described in Section 5.4) have been used
to increase the penetration of genes into the skin by the disruption of
the SC, increasing the drug penetration in underlying layers
[264,285–287]. Many studies have combined the use of NPs and physi-
cal methods for gene delivery. For instance, low-frequency ultrasound
was used to permeabilize the skin and facilitate liposome permeation.
When liposomes composed of DOTAP, DOPE, and DSPE-PEG2000 in a
molar ratio of 4.75:4.75:0.5 and siRNA-V600EB-Raf and siRNA-Akt3 at
a weight ratio of 10:1 were topically applied after ultrasonic treatment,
siRNA delivery into melanoma cells was enhanced. This approachPlease cite this article as: L.N. Borgheti-Cardoso, J.S.R. Viegas, A.V.P. Silves
cancer, Adv. Drug Deliv. Rev., https://doi.org/10.1016/j.addr.2020.02.005reduced the expression of the protein targeted by the siRNA sequence,
which suppressed melanoma development [285]. Gold NPs (AuNPs)
coated layer-by-layer with chitosan (LbL-AuNP) were designed as car-
riers for the iontophoretic delivery of STAT3 siRNA to treat MSC. The
STAT3 siRNA-loaded LbL-AuNPs, through an apoptosis mechanism, de-
creased cancer cell viability, and the iontophoretic application enhanced
the skin penetration of the siRNA-loaded LbL-AuNPs such that they
reached the viable epidermis [286]. ApDNA encoding IL-12 has also
been administered through physical methods such as a gene gun
[287] or electroporation [264]in MSC treatment.
6.4. Nanocarriers combined with physical methods
Physical techniques that enhance topical and transdermal drug de-
livery have been applied in the clinic since the 1980s and have emerged
as potential approaches for the treatment of skin cancers. Modalities
based on electrical, mechanical, or material structures and/or velocity
are used in combination with or associated with different types of NPs
to optimize percutaneous drug distribution or activation through differ-
ent mechanisms [288,289]. Thus, physical enhancement methods
(Fig. 4), especially laser irradiation (phototherapy, thermotherapy and
acoustic therapy), iontophoresis, ultrasound, and microneedles, have
been the focus of investigations into the treatment of MSC or NMSC
cases (Table 1).
6.4.1. Laser irradiation therapy
Photodynamic therapy (PDT) has been a therapeutic approach ex-
tensively explored throughout the scientific community and in the
medical clinic among other therapies based on laser irradiation sources.
This therapeutic approach takes advantage of the combination of a pho-
tosensitizer (PS) and a specific light wavelength that can induce the
production of highly reactive hydroxyl and singlet oxygen molecules,
which causes a series of biological, chemical and physiological reactions
and consequent cell death [290–292]. This review shows the main ad-
vantages of using NPs as platforms for specifically targeted delivery of
PSs to the tumor region. Lipid-based or polymer-based NPs loaded
with different PSs have also been the subject of research and have
proven to be a potential strategy for improving the penetration and ac-
tivity of these molecules in skin cancers [130,293–296].
Liquid crystalline nanodispersions (LCNs) capable of incorporating
different PSs [297] improved the skin penetration of protoporphyrin
IX (PpIX) according to in vitro and in vivo assays, compared to the
PpIX skin penetration seen with control formulations [130]. Encapsula-
tion of chlorin-e6 or meso-tetraphenylporphine-Mn(III) chloride, a
third-generation PS in LCNs, resulted in efficient internalization of
these PSs into malignant melanoma cells and exhibited significant
photodynamic effects after irradiation (10 J/cm2; 570 nm and 630 nm
filters) [296].
An SLN-loaded aluminum chloride phthalocyanine presented a 3.2-
fold reduction in the cell viability of the B16F10 cell line after irradiation
(0.5, 1.0, and 2.0 J/cm2; 670 nm filter) [293]. Another lipid-based NP, a
transethosome loaded with ferrous chlorophyllin (Fe-CHL), induced a
gradual decrease in tumor size in a murinemodel of melanoma, leading
to complete regression within 1 month after irradiation (720 J/cm2;
650 nm filter) with or without a kojic acid gel [294].
Fe-CHL-loaded polymeric NPs and polymeric-lipid hybrid NPs con-
jugated with the cycloRGDyk peptide induced phototoxicity in mela-
noma cells (B16F10 cell line) that were irradiated (26 J/cm2; 652 nm
filter). The results indicated that the selected ligand, cycloRGDyk, pos-
sessed a dual and simultaneously acting role as a disease-specific ligand
and an 1O2 quencher, making this nanoplatform a promising targeted
carrier for PDT [295].
Photothermal therapy (PTT), which generates heat in response to
applied laser light, has beenwell documented as a strategy for highly se-
lective cancer treatment and is mainly used with NPs that are embed-
ded within tumors. Hyperthermic effects can be directly achieved bytrini, et al., Nanotechnology approaches in the current therapy of skin
Fig. 4. Physical methods associated with the use of NPs to improve the delivery of therapeutic agents for the treatment of skin cancer: Microneedles, Electroporation, Iontophoresis,
Ultrasound and Laser therapy based in PTT (Photothermic therapy), PDT (Photodynamic therapy) and PAT (Photoacoustic therapy).
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ciated with the different NPs to induce an effective increase in the anti-
tumor effects. Then, the stimulation of these NPs by laser irradiation
leads to localized heat in the range of 40°C–45°C that causes cancer
cell death via apoptosis and necrosis. Another effect of PTT is an increase
in the vascular permeability of the tumor, which can facilitate antican-
cer drug delivery into the tumor [298,299].
In the field of skin cancer therapy, the photothermal properties of
different plasmonic NPs have been extensively investigated. Rahimi-
Moghaddam et al. (2018) found that conjugates of PEG-curcumin-gold
NPs potentiated the cytotoxic effects of curcumin in murine melanoma
cells after application of low-power NIR, and a considerable reduction in
tumor volume was observed in vivo after 48 h, with no impact on the
physical health of the animal [300]. In the studies of Singh et al.
(2018), a gold NP coating enabled liposomes to specifically absorb NIR
light. Destabilization of the liposomal core occurs via the heat generated
by the conversion of NIR light and thus increases the release of encapsu-
lated curcumin. The cytotoxic effects in murine melanoma cells in-
creased more than 80% after laser irradiation for 5 min and caused
irreversible cell damage. The addition of curcumin showed improved
cytotoxicity in cancer cells [301].
Similarly, cantharidin-loaded liposomes coated with gold NPs
showed disruption and release of the contents after exposure to NIR ir-
radiation. Significant differences in the cytotoxic effects were achieved
in vitrowhen different irradiation intensities were combined with lipo-
some applications. Additionally, cantharidin improved the efficiency of
photothermal therapy by suppressing HSP70 and BAG3 expression
and attenuating the antiapoptotic effects on tumor cells [302].Please cite this article as: L.N. Borgheti-Cardoso, J.S.R. Viegas, A.V.P. Silves
cancer, Adv. Drug Deliv. Rev., https://doi.org/10.1016/j.addr.2020.02.005Recently, immunotherapy and plasmonic NPs were combined as
an effective therapeutic strategy against tumor growth and for the
inhibition of metastases. When irradiated (1.0 W/cm2; 1,064 nm),
immunoadjuvant imiquimod (R837) loaded in cetyltrimethylam-
monium bromide-coated gold nanorods decorated with polyethylene
glycol and bovine serum albumin inhibited tumor growth and promoted
immune responses against the tumor (increased IL-12, IL-6 and TNF-α).
Additionally, treatment with the nanocomplex prevented lung metasta-
sis and tumor recurrence [303]. Chen et al. (2018) also used this thera-
peutic approach for synthesizing aluminum oxide (Al2O3) NPs coated
with polydopamine. The Al2O3 within the NPs, together with CpGs,
acted as an adjuvant to trigger cell-mediated immune responses that
could eliminate residual tumor cells and reduce the risk of tumor recur-
rence. The combination of the NPs with laser irradiation (1.18 W/cm2;
808 nm) efficiently killed the cancer cells within 5 min in vitro. In trials
in vivo, the survival was 3.9-to-6.3-fold longer than that in other groups
for the animal group that received intratumorally NPs. These results sug-
gest that a combination that inhibits both tumor recurrence and metas-
tasis is a potential therapy for skin cancer [304].
Photoacoustic therapy (PAT) is used to destruct target cancer cells. It
is based on the application of an enhanced photoacoustic shockwave
using a low-energy laser that damages the target cells by heating but
preserves the healthy cells [305,306]. Zang et al. (2016) reported a signif-
icant antitumor synergistic effect with the application of gold nanorods
containing three functional components (gold nanoparticle with photo-
acoustic effect and used as drug delivery platform, DNA to load doxoru-
bicin (DOX) and, folate functionalized). Treatment resulted in complete
healing of tumor lesions and minimal systemic toxicity in vivo [307].trini, et al., Nanotechnology approaches in the current therapy of skin
Table 1
Summary of main nanocarriers combined with a physical method for skin cancer therapy.
Physical method Nanocarrier Anti-cancer agent Main results Ref.
Laser irradiation – PDT Mesoporous silica NPs Vertoporphyrin NP treatment promoted a 50 to 70% reduction in cell proliferation
after 120 s and 180 s of red-light irradiation.
[290]
PEGylated gold NPs Mitoxantrone LED exposure alone did not cause significant cancer cell death. On
the other hand, the maximum PDT efficacy from NP was observed







NP containing photosensitizer demonstrated excellent
photodynamic properties and similar to free drug at a
concentration one order of magnitude larger.
[292]
Solid lipid NP Aluminum chloride
phthalocyanine
A two-fold increase in laser light radiation at 1.0 J/cm-2 promoted
greater phototoxicity of NPs, however did not alter the viability of
cells exposed to the free photosensitizer.
[293]
Transethosomes Ferrous chlorophyllin Mice having larger tumor volume (252.6 mm3) that were treated
in vivo by PDT, showed in a period of 7 days significant reduction
in tumor volume followed by complete tumor regression within 2
months of observation in more than 50% of the mice treated
[294]




Polymeric-lipid hybrid NP produced greater PDT cell death after 1
and 3 h of treatment, while this effect was achieved with
polymeric NP after 24 h. Moreover, PDT-mediated cytotoxicity of
melanoma cells results demonstrated a time-dependent effects.
[295]
Polymersomes Protophorphyrin IX PDT treatment after 1, 3, and 5 days showed that polymersomes
had a sustained anti-melanoma cell effect with significant tumor
cell population decrease after 3 and 5 days. Polymersomes
containing photosensitizer at 100 μg/mL killed more than 65% of
tumor cells and further, more than 63% of normal cells were alive
at the same conditions.
[296]
Laser irradiation – PTT PEGylated carbon nanotubes - In vivo PTT treatment using an 808 nm continuous-wave NIR laser
diode 808-2 W with the intensity of 8 W/cm2 for 10 minutes
showed that the average size of the tumor before and 3 days after
the NP treatment was decreased from 566.4 mm3 to 174.69 mm3
while in the control group this was increased from 406 mm3 to
745.31 mm3.
[297]
PEGylated gold NPs Curcumin The in vitro effect of gold NP upon irradiation by an 808 nm laser
for 10 min on melanoma cell line was clearly observed after laser
illumination while laser irradiation alone (without NPs
treatment) induced melanoma cell killing effect depending on
laser power. In vivo administration of gold NP associated with
laser irradiation resulted in effective destruction of melanoma
tumor cells.
[298]
Gold NP coated-liposome Curcumin After laser irradiation (780 nm for 5 min), the cytotoxicity of NPs
in presence and absence of curcumin was enhanced to 90% and
80%, respectively. These NP exhibited 9-fold reduction in cell
viability after laser irradiation in comparison with free curcumin.
[299]
Gold NP coated-liposome Cantharidin The drug released from NP increased the apoptosis of PTT-treated
tumor cells. The viability of cells not treated with NP and
irradiated showed slight decrease compared to control
(non-irradiated). The viability of NP treated cells decreased from




decorated with polyethylene glycol
and bovine serum albumin
Immunoadjuvant imiquimod
(R837)
The designed NP were efficient in direct tumor destruction
through PTT and trigger strong immune response with the help of
loaded immunoadjuvant in vitro and In vivo. In addition, NP under
laser irradiation inhibited cell metastasis.
[301]




Tumor eradication from combined photothermal therapy and
immunotherapy was observed to 50% of treated animals and the
survived for 120 days, which was the end point of the experiment.
This investigated strategy efficiently led to maturation of dendritic
cell, resulting in the secretion of cytokines and antibodies, just like
the proliferation of splenocytes and lymphocytes for anti-tumor
immunotherapy.
[302]
Carbon xerogel NPs - The in vivo tumor shrinkage from the combined treatment was
strongly increased when compared to non-treated group. An
intense necrosis rate was observed when was applied laser
irradiation after NPs injection in the tumor. Individual treatment
(laser irradiation or NPs alone) exhibited no toxic effect on the
tumor area.
[303]
Laser irradiation – PAT Gold nanorod Doxorubicin The photoacoustic effect of NP after 808 nm pulsed laser
irradiation exhibited direct physical damage to the cells. This
result was attributed to two distinct and complementary
mechanisms: the excellent photothermal property and high
photothermal conversion efficiency of the NP.
[304]
Light-responsive nanocapsules Doxorubicin The strategy based on the combination pulsed
microwave-triggered thermocavitation, gas burst and
chemotherapeutic activation exhibited significant tumor
reduction. In vivo, the animals demonstrated longer survival with
the combined treatment.
[305]
Iontophoresis Polymers-coated gold NPs Imatinib mesylate and STAT-3
siRNA
Noninvasive topical iontophoretic NP administration using anodal
iontophoresis at 0.5 mA/cm2 during 2 h was compared to
[306]
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Table 1 (continued)
Physical method Nanocarrier Anti-cancer agent Main results Ref.
intratumoral application. Reduction in tumor weight, tumor
volume and suppressed protein expression were increased by the
combined nucleic acid and chemotherapeutic drug in NP
compared to individual treatments.
Liposome STAT-3 siRNA and curcumin Anodal Iontophoretic application using a current density of 0.47
mA/cm2 during 4 h combined to multifunctional NP resulted in
5-fold greater drug deposition in viable skin compared to
non-iontophoretic drug delivery. The codelivery of drug and
nucleic acid from combined NP and iontophoresis exhibited an
increase in apoptosis events and significant reduction in cancer
cell growth compared to treatment of pure drugs and free nucleic
acid.
[307]
Nanoemulsions Zinc phthalocyanine The application of anodic iontophoresis at 0.5 mA/cm2 promoted
an accumulation of NPs after 30 min of treatment. The results
suggest that a longer time of electric current application is
necessary to favor the entry and a higher concentration of NP able




5-fluorouracil Subcutaneous treatments with NPs combined with anodal
iontophoresis at 0.5 mA/cm2 resulted in tumor shrinkage.
Similarly, cetuximab-functionalized NPs reduced tumor volume
after iontophoresis and subcutaneous injection.
[309]
Ultrasound Polymeric NPs Docetaxel and chlorin e6 Sonodynamic therapy combined with NPs exhibited higher rates
of apoptosis and necrosis compared with the individual and dark
treatments. In addition, when NP was exposed to ultrasound, a
large amount of ROS was found, leading to mitochondrial damage




Curcumin and topotecan Reduced tumor growth rate was observed to the ultrasound
exposed when compared to left tumor (not exposed with
ultrasound) suggesting that the ultrasound exposure leads to
localized mild hyperthermia and that would have also contributed
in reducing tumor size through non-coagulative necrosis. Also, the
tumor growth was reduced by 3.5 and 14.8 times to the
ultrasound exposure treatment as compared to the unexposed
and group treated with physical mixture of unloaded drug
respectively. Further, survival analysis showed that the 26% of the
animals were alive in untreated group whereas 93% were alive at
the end of treatment with NP and ultrasound.
[311]
Microneedle PEGylated gold nanorod and micelles Docetaxel The tumor treated with associated microneedles and
photothermal therapy reached 50 °C within 1 min, which
promoted an irreversible damaged and improved therapeutic
efficacy results compared to non-combined treatments.
[312]
Gold nanocage Doxorubicin Combined microneedle and photothermal treatments have
stronger inhibition capability on tumor growth. The final tumor
volumes and tumor weights evaluated at 12 days of treatment
were relatively lower for combined treatments in presence of
chemotherapy drug than in the absence of chemotherapy drug.
[313]
Liposome Doxorubicin and celecoxib In vivo, topical application of the microneedle and through
co-loaded NPs resulted in a significant decrease in mean tumor
weight. Treatment with NPs alone showed a smaller tumor
reduction compared to combined therapies.
[314]
Mesoporous organosilic NPs Phthalocyanine and with small
molecule inhibitors (dabrafenib
and trametinib)
There was no significant difference of NP amount skin release
between the untreated and microneedle-treated skin samples at
the first 10 minutes. Them, one hour later, the microneedle
treatment increased the NP skin penetration rates dramatically
which were 63% compared to 27.2% for treatment without
microneedle. For in vivo treatment in xenografted tumor mouse
model, the tumor growth curve of untreated group exhibited
exponential growth of tumors, while photodynamic therapy
combined with NPs effectively reduced this growth.
[315]
pH-responsive lipid NPs Cisplatin Treatments with microneedle and NP significantly increased
apoptosis and cytotoxicity in tumor cells, exhibiting a significantly
reduced tumor weight and volume in xenograft tumor animal
model.
[316]
Applications reported in the last three years (2017-2019).
Abbreviations: PDT = Photodynamic Therapy; PTT = Photothermic Therapy; PAT = Photoacoustic Therapy.
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responsive nanocapsules demonstrated significant antitumor activity
in vitro and in vivo. It was reported that after pulsed microwave
irradiation, the nanocapsules absorbed energy to generate a large
thermoacoustic shockwave that simultaneously decomposedmolecules
into carbon dioxide and ammonia, causing cavitation and, consequently,
cellular damage. The thermoacoustic shockwave and the gas burst alsoPlease cite this article as: L.N. Borgheti-Cardoso, J.S.R. Viegas, A.V.P. Silves
cancer, Adv. Drug Deliv. Rev., https://doi.org/10.1016/j.addr.2020.02.005mechanically disrupted intracellular organelles, which resulted in a
high ratio of necrotic cells, and DOX was released from the cytosol
into the nucleus to initiate cell death [308].
6.4.2. Iontophoretic therapy
Iontophoresis is a type of electrotherapy used to promote the perme-
ation of drugs into the skin and is mainly used for the administration oftrini, et al., Nanotechnology approaches in the current therapy of skin
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two electrodes (anode and cathode) are placed on the surface of the
skin, and a constant or pulsed electric current (0.1–1mA/cm2) is applied
and dispersed through a solution containing the drug. This causes a drug
iontophoretic flux through the skin, which refers to the sum of the
electromigration and electroosmosis effects [289,309]. Several preclini-
cal and clinical studies have evaluated the transdermal iontophoretic re-
lease of skin cancer treatments, including chemotherapy, vaccines,
photosensitizers, and oligonucleotides [309]. Moreover, iontophoresis
is promising for improving the permeation of NPs loadedwith therapeu-
tic agents.
In studies by Labala et al. (2015, 2016, 2017), polymer-coated gold
NPs (GNPs) were investigated for the topical iontophoretic administra-
tion of imatinib mesylate (IM) and STAT-3 siRNA [286,310,311]. The re-
sults showed that iontophoresis (0.47 mA/cm2) increased the
penetration of the IM-loaded GNPs by 6.2-fold compared to the passive
application and promoted greater retention in the viable skin [311].
Similarly, the application of iontophoresis increased the penetration of
GNP-siRNA STAT3 into the skin. Treatment with GNP-siRNA STAT3 in
murine melanoma cells exhibited a reduction in STAT-3 expression,
and events related to early and late apoptosis were observed. The ionto-
phoretic codelivery of STAT-3 siRNA and IM-loaded GNPs in a murine
melanoma model showed results similar to those of the intratumoral
application: a significant reduction in the percentage of tumor volume
and tumorweight and suppressed STAT-3 protein expression compared
to that seen with treatment with GNPs with STAT-3 siRNA or IM [312].
Iontophoretic delivery of the STAT-3 siRNA complex into curcumin-
loaded liposomes also showed promising results against epidermoid
carcinoma cells [310,313]. Iontophoretic application (0.47 mA/cm2) of
liposomal curcumin resulted in the accumulation of curcumin in viable
skin at a level that was 5-fold higher that that seen after the four-hour
passive application of free curcumin [310].
In other studies, the use of iontophoresis improved the epidermal
penetration profile of PAMAM loaded with an antisense oligonucleo-
tide (directed to the Bcl-2 protein) and 5-FU-loaded immunoli-
posomes functionalized with an anti-EGFR antibody (cetuximab).
The results in amurinemodel of skin cancer confirmed the therapeu-
tic efficacy with a reduction in tumor volume and cellular prolifera-
tion [314,315].6.4.3. Ultrasound and electroporation therapy
Ultrasound and electroporation, electricity-based modalities, have
not been extensively explored to determine their combined effects on
NPs. The effects of ultrasound on tissues and cells include cavitation,
thermal increases, and acoustic creep. After electroporation, a transient
increase in the permeability of cell membranes occurs under the influ-
ence of an appropriately modulated electric field [289,316,317]. Liu
et al. (2018) reported antiproliferative and antimetastatic effects
in vitro and in vivo in a murine model of melanoma treated with doce-
taxel and chlorin e6 (Ce6)-loaded NPs and the application of low-
intensity ultrasound (1 W/cm2) [318].
Prasad and Banerjee (2019)were the first to report the development
of nanoconjugate and microbubble (MB) nanocapsules that were asso-
ciated with ultrasound-mediated co-delivery of hydrophobic and hy-
drophilic drugs (curcumin and topotecan). The results showed that
exposure to ultrasound (2 W/cm2) was significant in reducing the tox-
icity induced by free drug concentrations of curcumin and topotecan
in vitro that was accompanied by an increase in necrotic and apoptotic
cells. In a murine model of MSC, a reduction in tumor growth was ob-
served. These results suggest that the ultrasound application facilitated
tumor permeabilization and that insonation catalyzed release on de-
mand and thus facilitated simultaneous release and internalization. Ad-
ditional factors may have played a role in tumor reduction, such as
energy production by cavitation, ROS formation, and localized mild hy-
perthermia that led to noncoagulative necrosis [319].Please cite this article as: L.N. Borgheti-Cardoso, J.S.R. Viegas, A.V.P. Silves
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Among the physical methods used to deliver drugs, microneedle
(MN) technology has been frequently used to facilitate the intrader-
mal/transdermal delivery of drugs in a minimally invasive manner
[289,320]. Briefly, the MN mechanism of action is based on disruption
of the skin layer to create micrometer-sized pathways through which
the drug is directly applied to the epidermis or the upper dermis region,
from where it passes into systemic circulation without facing a barrier
[320,321].The combined use of MNs and NPs has been leveraged to
achieve the release of low-weight drug molecules in the dermis and
for transcutaneous immunization [289,321].
Hao et al. (2017) demonstrated improved antitumor efficacy against
epidermoid carcinoma when micelles loaded with docetaxel were de-
livered by a near-infrared (NIR)-responsive PEGylated gold nanorod
(GNR-PEG)-coated poly(l-lactide) microneedle system (GNR-PEG-
MN). In the tumor region, the transcutaneous penetration of GNR-PEG
increased with the application of MNs. The combination of the MN sys-
tem with docetaxel culminated in tumor eradication and no recurrence
during the study period. Notably, the results demonstrated that the de-
livery of GNR-PEG and docetaxel via MNs was safe and could be used to
reduce the chemotherapeutic dose needed [322]. In the investigations
by Ahmed et al. (2019), treatment with liposomes loaded with doxoru-
bicin (DOX) and celecoxib via solid MNs promoted superior antitumor
results. MN pretreatment increased the penetration of liposomes by ap-
proximately 2-fold compared to passive delivery. The application of li-
posomes coloaded with DOX and celecoxib significantly inhibited
tumor growth in melanoma xenograft mouse models compared to the
application of liposomes loaded with a single drug. However, in the
group in which MNs were preapplied, the antitumor effects were
more effective [323].
MNs have been associated with photodynamically active mesopo-
rous organosilica NPs to enhance the effects of PDT. NPs produced
with phthalocyanine covalently bound to the silica matrix dramatically
increased the quantum yield and photostability. The mesopores of the
NPs were further loaded with dabrafenib and trametinib, which target
the hyperactive mitogen-activated protein kinase (MAPK) pathway
for melanoma treatment. Skin pretreatedwith amicroneedle presented
an increased fluorescence signal in both the epidermis and dermis. In
tumor regression studies with a xenografted melanoma mouse model,
the superior therapeutic efficacy of the NPs was confirmed through a
combination of photodynamic therapy and targeted therapy [324]. In
another study, Lan et al. (2018) investigated the application of MNs
and found that their use improved the penetration of pH-responsive
lipid NPs loaded with cisplatin that were used for targeted antitumor
therapy. In a xenograft animal model, it was demonstrated that MNs
loaded with cisplatin NPs significantly increased the cytotoxic effects
in and the apoptosis of cancer cells, resulting in a significant reduction
in the tumor size. The tumor growth inhibition ratios in the group
with MN-delivered cisplatin-loaded NPs were 76%, which is considered
a promising antitumor effect. Moreover, no serum platinum levels,
nephrotoxicity, pulmonary toxicity or hepatotoxicity were detected
in vivo, indicating the safety of this technique [325].
6.5. Multifunctional delivery systems
Advances in understanding the progression and survival of cancer
have led to increased interest in developing innovate therapeutic inter-
ventions. In this context, the design of multifunctional delivery systems
that carry at least two bioactive molecules with different pharmacolog-
ical and physicochemical properties against cancer has been the focus
of extensive investigations for potential therapeutic strategies
[11,326–328]. For skin cancer therapy, multifunctional delivery systems
have been developed for the delivery of at least two molecules and/or
the combination of chemotherapeutics, bioactive compounds of natural
origin, immunotherapeuticmolecules and siRNAs and have been shown
to be beneficial compared to single bioactive molecules. This strategytrini, et al., Nanotechnology approaches in the current therapy of skin
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summary of the applications of this approach is shown in Table 2.
DOX and paclitaxel (PTX) are chemotherapeutic drugs commonly
used in multifunctional nanocarriers and have different pharmacologi-
cal mechanisms and cellular targets. Solid lipid NPs were used to
codeliver paclitaxel (PTX) and ascorbyl palmitate to treat murine mela-
noma that hadmetastasized to the lungs ofmice and provided synergis-
tic antitumor effects in vitro and in vivo. It has been reported that this
treatment actively suppressed tumor growth and eliminatedmore can-
cer cells from the lungs than treatmentwith lipid NPs loadedwith a sin-
gle drug via a synergistic effect that reduced the Bcl-2/Bax ratio [329]. In
addition, PTX-loaded SLNmodified with Tyr-3-octreotide has also been
shown to reduce tumor volume in murinemelanomamodels and to in-
duce antimetastatic and immune responses (an increase in IL- 12, IFN-γ
and TNF-α) [330]. In another study of melanoma models, PTX-loaded
hyaluronic acid micelles modified with tocopherol succinate (TOS)
were able to accumulate in the tumor to induce the EPR effect, the
redox sensitivitywas able to control release of thedrug, and dissociation
of the TOS led to synergistic antitumor effectswith PTX treatment [331].
The codelivery of PTX and ceramide C6 in nanoemulsions, developed
by Carvalho et al. (2017), showed a synergistic antitumor effect in mel-
anoma cells. Coencapsulation of PTX and ceramide decreased the con-
centration necessary to reduce cell viability by 2.5-4.5-fold to 50%
(EC50), indicating a synergistic effect [332]. In other studies, codelivery
of ceramide and DOX through lipid nanocarriers was effective in en-
hancing the antitumor efficacy of DOX in vitro and inmurinemelanoma
models [333,334]. Wang et al. (2017) reported an antitumor efficacy of
93.94±2.77% for a multifunctional nanocarrier, a finding that was sig-
nificantly higher than that of a single drug-loaded nanocarrier and
the Duopafei® control [334]. More recently, a combined therapy of
DOX and the autophagy inhibitor wortmannin was improved by Cu
(I)-catalyzed click chemistry-triggered aggregation of azide/alkyne-
modified micelles. After the micelles reached the tumor in vivo, the
catalysts were intratumorally injected, resulting in aggregation of the
micelles induced by the click reaction. Furthermore, the decreased
amount of autophagosomes, the expression of LC3-II, and the increased
level of p62 confirmed the inhibition of autophagy and the synergistic
effect in suppressing melanoma and breast cancer in mice [335].
Bioactive compounds of natural origin are known for their multiple
biological activities, and in antitumor therapy, their effect in combina-
tion has been the focus of several studies. Curcumin and chrysin
coencapsulated in PLGA-PEG NPs exhibited a significant decrease in
the expression of metalloproteinase-2 and -9, which are enzymes asso-
ciated with the invasion and metastatic ability of cancer cells, in a mu-
rine melanoma model [336]. An additive effect on the codelivery of
curcumin and topotecan in nanocapsules was demonstrated, and it
was reported that the IC50 after ultrasound exposure was reduced by
150-fold and 100-fold compared to that found with treatment with
free curcumin and topotecan, respectively [319]. Another example of a
natural compound codelivered with a chemotherapeutic compound
was reported by Mishra et al. (2019). The functionalized hyaluronic
acid liposomes coloaded with eugenol and dacarbazine exhibited a 9-
fold and 2-fold increase in induced cytotoxicity in melanoma cell lines
compared to that induced by free dacarbazine and eugenol-loaded lipo-
somes, respectively. An increase in the number of late apoptotic cells
was found (45.16% vs. 8.43%), together with a significant inhibition of
cell migration and proliferation. These results indicate that when deliv-
ered in combination with eugenol, the dose of dacarbazine needed for
chemotherapy is reduced, leading to an implied reduction in undesired
toxicity [337].
Using an immunotherapy and nanovaccine approach, Zhuang et al.
(2016) proposed the synthesis of hybrid lipid-coated zinc phosphate
NPs to coencapsulate antigenic peptides (TRP2180-188and HGP10025-
33) and monophosphoric lipid A (MPLA). Data from studies conducted
in vitro and in vivo (metastatic melanoma model) showed that the sys-
tem coloaded with peptides and MPLA was effectively captured byPlease cite this article as: L.N. Borgheti-Cardoso, J.S.R. Viegas, A.V.P. Silves
cancer, Adv. Drug Deliv. Rev., https://doi.org/10.1016/j.addr.2020.02.005dendritic cells with distinct time-dependent accumulation and cytokine
enhancement, such as increases in IL-12, IFN-γ and TNF-α, which
are related to the efficiency of T cell activation. A reduction in angiogen-
esis and a minimal number of metastatic lung nodules were also
observed [338].
To enhance the antitumor immune response, Lu et al. (2018) dem-
onstrated that codelivery of CpGs and OVA in biodegradable
glutathione-depleted dendritic mesoporous organosilica NPs produced
increased cytotoxic T lymphocyte activity and led to reduced tumor
growth in a murine melanoma model [339]. Similar antitumor effects
and immunization levels were achieved in the investigations of Zhang
et al. (2018) through the coloading of CpGs, tyrosinase-related protein
2 (Trp2) peptides and twomutated epitopes (M27 andM30) in layered
double hydroxide NPs. Significant inhibition of tumor growth (approx-
imately 50%) in themousemelanomamodelwas observed [340]. Treat-
mentwith CpGs andDOX coloaded onto dendrimers has been shown to
enhance the immune response induced by DOX and to suppress tumor
growth and metastasis synergistically. Additionally, due to the coating
of the dendrimers with antimetastatic low-molecular-weight heparin,
platelet-induced epithelial-mesenchymal-like transition was
prevented, which disrupted the arrangement of tumor cells via changes
in the actin cytoskeleton, resulting in suppression of themigration abil-
ity of the tumor cells [341].
Immunotherapy combined with chemotherapy has also been pro-
posed as a strategy to improve antitumor effects by distinctmechanisms
[342–344]. PTX and IL-2 coloaded on thermosensitive NPs showed sig-
nificant inhibition of melanoma tumor growth (88%) and metastasis
and prolonged overall survival for tumor-bearing mice compared with
monotherapies. In addition, activation of innate and adaptive immunity
in the tumor microenvironment was observed [342]. In another study,
DOX-loaded liposomes were functionalized with a T cell receptor
(TCR)-like antibody (scFv G8 and Hyb3) directed against themelanoma
antigen A1 (MAGE-A1) that is presented by human leukocyte antigen
A1 (M1/A1) [345]. The accumulation of targeted liposomes was 2-to-
2.5-fold and 6.6-fold enhanced in vivo compared with that of
nontargeted liposomes and free drugs, respectively. The superior antitu-
mor activity of the MAGE-A1-targeted DOX-loaded liposomes was ob-
served in tumors with positive M1/A1 expression [345]. The
functionalization of the 5-FU-liposomes with cetuximab was also
shown to improve antitumor effects with a great reduction in mela-
noma tumor volume (N60%) compared to that induced by the free 5-
FU or control liposomes [346].
Gene therapy, such as that based on siRNA, can be used to suppress
the production of cancer target proteins effectively. In combinationwith
chemotherapeutics, it can improve targeting selectivity and counterbal-
ance drug resistance, thereby increasing therapeutic efficacy synergisti-
cally. Furthermore, combination therapy can enable the reduction of the
required dose of individual chemotherapeutic agents, which conse-
quently reduces potential adverse drug reactions [87,347]. Bcl-2 siRNA
and PTX coadministered in pH-sensitive liposomes exhibited a marked
antitumor effect in melanoma cells compared with that found when
free PTX was applied [348]. In this study, PTX-inducible drug resistance
(antiapoptotic response)was observed butwas effectively decreased by
the parallel silencing of the Bcl-2 gene during the administration of che-
motherapy, and significant overexpression of Bax (proapoptotic in-
ducer) and down regulation of pro-caspase-3 were observed,
indicating activation of cellular apoptosis [348]. Duan et al. (2018) de-
veloped liposomes containing an Aurora kinase inhibitor (XY-4) and
Bcl-xl siRNA to enhance antitumor effects through distinct mechanisms
of cell cycle arrest and induction of apoptosis. Inmurinemelanoma cells,
liposomal delivery exhibited strong anticancer effects in a
concentration-dependent manner and increased efficacy of the
codelivered agents. The authors reported that the combination of XY-4
and Bcl-xl siRNA resulted in cell apoptosis through a mitochondrial-
based signaling pathway (via caspase-9 and caspase-3). The multifunc-
tional liposome treatment exhibited a significant reduction in tumortrini, et al., Nanotechnology approaches in the current therapy of skin
Table 2
Multifunctional NPs reported in the last three years (2017–2019).
Nanocarrier Anti-cancer agent Functionalization Functionalization:
Target /Mechanism of action
Key studies Ref.




Tumor targeting, mainly in
pulmonary metastases.
Development of PLGA-NP for protection





- - Development of NP co-loaded with
curcumin and topotecan for therapeutic
regimen for spatiotemporal delivery of dual
drug for treatment of cancer.
[319]
Paclitaxel and IL-2 mPEG-PLGA Stabilization of NPs and
prolongation of circulation time.
Study of antitumor and immunostimulant





mPEG-PLGA PEG Prolongation of circulation time. Development of dual-sensitive NP for
co-encapsulating doxorubicin and
interferon-γ and to realize the codelivery of





PEG Better ability to reach tumor layers
and stability.
Investigation of the co-encapsulation of
curcumin and chrysin in PLGA-PEG-NP in




Anti-CD20 antibody Specific binder targeting (CD20 is is
a marker of melanoma-initiating
cells).
Investigation of efficiency all-trans retinoic
acid -loaded PLGA-NP conjugated to






Prolongation of circulation time,
decrease the nonspecific
distribution in nontumor tissues,
and increase the tumor
accumulation.
Micellar NP loaded with dasatinib were
produced with functional polymers as a
strategy to improve drug efficacy, tumor




mPEG-SS mPEG-SS conjugated paclitaxel has
disulfide bond sensitive to redox
capable of releasing a drug in the
tumor microenvironment (acid).
Development of micelle system based on
redox-sensitive mPEG-SS-paclitaxel and
mPEG-SS-doxorubicin conjugate by
synchronized and controlled release.
[357]
Paclitaxel Tocopherol succinate Increase the tumor accumulation
and dissociation in redox
environment and drug release.
Development of paclitaxel-loaded micelles
formed by conjugated tocopherol succinate
and hyaluronic acid to improve delivery,





- - Developed of strategy for the codelivery of
doxorubicin and wortmannin in




Doxorubicin 3-aminophenylboronic acid, LMWH
and D-α-tocopheryl succinate
conjugates
Development of multifunctional micelles
formed by antimetastatic components as
carrier of chemotherapeutic agent
(doxorubicin).
[358]
Hybrid micelle CpG and Trp2
peptide
- - Design of polymeric hybrid micelles as a
simple and potent antigen/adjuvant
codelivery system with highly tunable to





LMWH Inhibition of tumor cell and platelet
interaction and protection of CpG
against reticuloendothelial system
clearance and potential cationic NP
toxicity.
Coated-anti-metastatic low molecular
weight heparin dendrimers loaded with
doxorubicin and immunoadjuvant CpG as a
strategy to promote immune, antitumor
and anti-metastatic activation effects.
[341]
Hybrid NP siRNA Bcl-2 Derivative thiolated hyaluronic acid
(redox-sensitive)
Colloidal stability, prolongation of
circulation time and dissociation in
redox environment and drug
release.
Production of calcium phosphate NP
complexes complexed with siRNA and
coated with disulfide cross-linked
hyaluronic acid as an intelligent system for
selective release of siRNA through




Salinomycin Anti-CD20 aptamers Specific binder targeting (CD20 is is
a marker of melanoma-initiating
cells)
Design of lipid-polymer-NP to improve the
delivery of salinomycin and targeting






DSPE-PEG2000 and mannose Specific binder targeting
(preferential uptake by the
dendritic cells in the lymph nodes
after subcutaneous administration)
Development of lipid-coated calcium
phosphate NP and functionalized with
PEG-mannose to direct uptake by






- - Development of SLNs co-loaded with
ascorbyl palmitate and paclitaxel for
synergistic therapy in metastatic
melanoma.
[329]
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Table 2 (continued)
Nanocarrier Anti-cancer agent Functionalization Functionalization:
Target /Mechanism of action
Key studies Ref.
Paclitaxel Tyr-3-octreotide Specific binder targeting and
increased immunogenic response.
Design of paclitaxe-loaded SLN
funcionalized with Tyr-3-octreotide






2-hydroxyoleic acid Colloidal stability of liposomes and
anti-tumor selectivity.
Design of liposomes composed of
2-hydroxyoleic acid, an antitumor agent,
and loaded with a chemotherapeutic agent.
[362,
357]
Liposome 5-fluorouracil Cetuximab Specific binder targeting through
receptor ligands expressions on
tumor cell surface (IgG antibody
that has affinity for EGFR).
Conjugation of cetuximab into
5-fluouroacil-loaded liposome to improve
targeted delivery in squamous cell





Hyaluronic acid Specific binder targeting through
receptor ligands expressions on
tumor cell surface (CD44 receptors).
Development of liposomes loaded with
eugenol and dacarbazine and coated with
hyaluronic acid to confer targeting
cancer-initiating cells and overcoming





- - Development of ceramide-based liposomes
and loaded with doxorubicin as a system to







- - Co-administration studies of the newly
synthesized Aurora-A kinase inhibitor XY-4




Doxorubicin Antibody (scFv G8 and Hyb3) Specific binder targeting through
receptor ligands expressions on
tumor cell surface (melanoma
antigen A1)
Studies of the efficacy of
doxorubicin-loaded liposomes directed
against melanoma antigen A1 by
conjugation with T-cell receptor-like








- - Investigation of the liposomal co-delivery
of curcumin and STAT3 siRNA by
non-invasive topical iontophoretic
application to treat skin cancer.
[310,313]
Transfersomes Paclitaxel Cell-penetrating-peptide (R8H3) Increased penetration into the skin
and tumor stroma as well as more
efficient transport into tumor cells.
Development of a hydrogel
oftransfersome-embedded oligopeptide to









- - Studies of the efficacy of co-delivery
paclitaxel and C6 ceramide in micro and
nano-emulsions containing tributyrin (a








- - Development of ceramide-based
nanosuspension with docetaxel to exhibit a
synergistic therapeutic effect.
[334]
Silica NP Dacarbazine Folic acid-grafted liposomes Specific binder targeting through
receptor ligands expressions on
tumor cell surface.
Rationally designed of hollow mesoporous
silica NP for the encapsulation and targeted
(folic acid-grafted liposomes) release of






Electrostatic attraction and antigen
loading. And, sensitive-redox bonds
activate immune system and
immunogenic activity against the
tumor.
Development of glutathione-depletion
mesoporous organosilica NP by codelivery
of antigen protein (OVA) and a toll-like
receptor 9 agonist into antigen presenting
cells and induced endosome escape.
[236]
Gold NP Mesilato de
imatinibandsiRNA
STAT-3
- - Production of layer-by-layer assembled
gold NP containing imatinib mesylate and
anti-STAT3 siRNA delivery in melanoma





Cationic lipid (DOTAP, DOPE,
cholesterol) DSPE-PEG2000 and TAT
peptide
Protection, guidance and specific
release.
Design of TAT peptide-modified gold NP
condensed with Cas9-sgPlk-1 plasmids and
coated lipids to allow cellular delivery and








- - Studies of constructing Layered double
hydroxide NP-based multi-target
therapeutic cancer vaccine, using peptides
antigens and two mutated epitopes.
[238]
Abbreviations: PLGA = polylactic-co-glycolicacid; IL-2 = interleukin-2; IFN-γ = interferongamma; mPEG = methoxypolyethyleneglycol; PEG = propyleneglycol; MMP2 =
matrixmetalloproteinase 2; DSPE-PEG2000 = 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)-2000]; LMWH= Low molecular weightheparin; CpG
= cytosine-phosphorothioate-guanineoligodeoxynucleotides; Trp-2 = tyrosinase-relatedprotein 2; siRNA = smallinterfering; Bcl-2 = B-celllymphoma 2; PD-L1 =
programmeddeath-ligand 1;mRNA=micro RNA; STAT-3= signaltransducerandactivatoroftranscription 3; OVA=ovalbumin; TAT peptide=HIV cell-penetratingtransactivatorprotein.
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approach, the codelivery of programmed cell death protein 1 siRNA
and tyrosinase-related protein-2 mRNA in lipid-coated calcium phos-
phate NPs was shown to increase anticancer immunization, which
was accompanied by significant inhibition of tumor growth and metas-
tasis, in a murine melanoma model [350].
In addition to carrying at least two bioactive therapeutic agents, a
multifunctional delivery system can also be designed to perform other
functions to surpass biological barriers and effectively deliver their
loads to the target tissue/organ. Functionalization is a strategy that al-
lows the delivery system to have extra function, for example, to allow
longer circulation time and reach the desired location by the EPR effect
or through interactions with ligands or to be able to respond to specific
stimuli from the pathological microenvironment [104]. A summary of
the functionalization of NPs used in skin cancer is also presented in
Table 2.7. Conclusion and future perspective
Nanotechnology has established a science that has changed the way
we face the challenges of new disease treatments, and this technology
allows us to go beyond what conventional treatments are capable of.
Nanomedicine for skin cancer has already become a current scientific
practice, and it has demonstrated in recent years a major evolution in
the treatment of solid skin tumors, including aggressive and invasive tu-
mors, by various routes of administration, aswell as initial tumor lesions
by less invasive routes of administration such as topical route.
Regardless of the route of administration, the use of NPs to carry ac-
tive molecules or their combination is attractive for reducing the tumor
mass, and this is a recurrent result in scientific research. Individualized
and specific therapies have been made possible with the use of NPs, as
have a reduction in drug concentrations, which leads to a lower inten-
sity of adverse effects compared to conventional chemotherapies.
In conclusion, NPs enable therapies such as immunotherapies and
gene therapies to be used in more efficient ways, which is important
since they are high-cost therapies. The versatility of these nanocarriers
grows exponentially because although their use adds to the cost of ther-
apy, it comes with innumerable benefits, which in terms of cost-
effectiveness, are worth conceding, as these benefits lead to greater
prospects for diagnosis and treatments, in addition to allowing the use
of theranostics in cancer patients. As with other strategies, the use of
NPs couldmake both types of therapies feasible for clinical applications.
As discussed in this review, although the nanotechnology field offers
several strategies to fight cancer, many efforts are still needed to gener-
ate effective and safe therapies.Acknowledgments
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